前往化源商城

53-41-8 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1266185
Protocol: N/A
Comment: Journal: Nat Chem Biol
Year: 2007
Volume: 3
Issue: 5
First Page: 268
Last Page: 273
DOI: 10.1038/nchembio873
Standard TypeStandard UnitsActivity Comment
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR541
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO, was added using a Flying Reagent Dispenser to generate a final concentration of 50 nM CITCO inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inhibitor3.349141.215910Single point of activity-5.47514.95490.5085-42.7363-1.5203-30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-8.087121.89-8.6781-3.6855-6.25695.4433-2.2253-6.5947-10.7583-4.5705-16.1608-16.3686-5.5938-8.0871QC'd by ACCInactive0
Inhibitor2.660331.350422Complete curve; partial efficacy-5.57514.95490.7593-35.7832-4.4328-1.20 0 0 0 0 0 0 0 0 0 0 0 0 1 1-7.07487.0287-3.7117-8.93987.0191-8.6003-10.5811-9.6323-3.5772-9.7824-21.4714-32.0269-13.6825-7.0748QC'd by ACCInactive0
Inhibitor29.8493180.333140Partial curve; high efficacy-4.52511.86170.9403-183.9808-3.6476-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-139.3794-6.9891-4.5485-2.48725.72942.1105-4.4422-5.01950.98326.5263-18.8291-30.3545-53.8001-139.3794QC'd by ACCInhibitor29.8493162.790140Partial curve; high efficacy-4.52513.24750.9553
Inactive0-4.77512.40640.4777-19.93010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.4418-5.3665-6.0776-0.6378-0.7746-5.95928.056814.4063-4.2029-2.83313.6942-1.1786-14.0414-17.4418QC'd by ACCInactive0-4.57513.1320.6731
Inactive0-4.04014.95490.487724-5.718340 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6907-9.6058-16.8485-11.179-0.45450.0756-9.022-7.6078-4.898-2.6992-0.66814.3314-11.422917.6907QC'd by RTIActivator64.553243.03530Partial curve; partial efficacy-4.19013.92950.9117
Inactive0004-19.84863.3433-23.4364-34.1329-6.2414-5.0556-25.546-8.9103-6.9329-28.1976-6.81633.8592-42.036-19.8486QC'd by RTIActivator67.057937.01130Partial curve; partial efficacy; poor fit-4.17353.67720.7941
Inactive0-4.02734.95490.655322-3.294740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.0345-2.80161.8842-7.0081-1.7985-7.3345-5.4629-6.0156-0.7765-1.4972-8.9956-1.9725-7.487516.0345QC'd by RTIInactive0-4.27732.33320.6095
Inactive00047.8644-12.2433-5.1181-4.04961.28844.3493-4.5231-6.8637-4.8147-7.4445-2.1022-11.7632-20.07367.8644QC'd by RTIInactive0-4.37991.96730.5769
Inactive000412.77776.2553-5.7998-3.9544-6.27073.8508-4.3153-0.2911-4.79463.74813.8044.64191.374312.7777QC'd by RTIInactive0-4.28464.95490.3638
Inactive0-4.20534.44950.6434-17.42521.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.7713.79853.86442.4904-4.2833.78225.42352.6092-2.38-3.39182.70615.627-2.5037-15.771QC'd by RTIInactive0-5.20534.95490.321
Inhibitor5.9059106.654984Complete curve; high efficacy-5.228710.9844-102.49964.1553-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.8049.49943.6503-0.42471.07452.82466.38180.0721-15.1461-24.7454-55.3584-79.6141-94.3827-85.804QC'd by RTIInhibitor4.691398.416784Complete curve; high efficacy-5.32870.90.9674
Inactive0-4.69341.55790.702223-4.449740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3595-2.1806-3.3591-6.2651-0.28090.121-6.0475-11.7066-7.89250.86856.2708-0.375526.069416.3595QC'd by RTIActivator71.880946.06290Single point of activity-4.14344.95490.7673
Inhibitor69.1718135.093943Partial curve; high efficacy-4.16013.06540.9789-149.2252-14.1313-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-117.8714-2.1311-17.2291-13.9078-13.6919-19.6465-13.3695-15.7919-17.4807-14.0473-10.7354-16.145-44.1916-117.8714QC'd by RTIInhibitor54.9451147.633342Partial curve; high efficacy-4.26012.40640.9628
Inactive0-6.14174.95490.4637-11.0778-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.73651.2389-2.2448-12.4683-0.62132.0757-1.40511.6174-8.0337-11.8106-11.9614-1.3448-17.9815-2.7365QC'd by RTIInactive0-4.34170.50.4602
Inhibitor8.844263.970182Complete curve; high efficacy-5.05331.46410.9355-69.4155-5.4454-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.4281-3.3461-7.3817-5.25411.5957-7.1494-6.1151-2.5632-12.7008-17.0044-40.829-49.2957-77.8583-59.4281QC'd by RTIInhibitor7.882431.683321Complete curve; partial efficacy-5.10332.33320.905
Inhibitor19.477457.938541Partial curve; partial efficacy-4.71051.34430.9334-57.56260.376-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0338-12.41210.71942.24359.20663.0773-1.07773.1429-3.055-5.8935-11.5387-32.2284-42.404-52.0338QC'd by RTIInhibitor77.540938.538210Single point of activity-4.11054.95490.5991
Inactive0004-3.3574-9.0659-5.0523-7.9611.8345-6.6475-6.4054-4.0807-7.994-5.2589-4.8636-18.8381-16.5327-3.3574QC'd by RTIInactive0-5.70264.95490.3553
Inactive0-4.09594.95490.659231.5-0.506240 0 0 0 0 0 0 0 0 0 0 0 0 0 025.14185.9174-1.2243-9.58850.3121-2.79136.44825.5515-1.4762-0.4167-3.92814.3971-4.45225.1418QC'd by RTIActivator56.764849.34910Partial curve; partial efficacy-4.24591.80790.7545
Inactive000411.60064.5643-3.7194-10.097311.42282.41525.31161.6689-4.6133-3.7747-3.13611.8656-13.87311.6006QC'd by RTIInactive0-4.14513.29750.4562
Inactive0-4.06414.95490.569122-3.35640 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3590.1187-1.3367-4.6228-5.1472-1.2162-0.1657-0.04880.0689-5.7723-5.23-1.7902-11.963316.359QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR611
Protocol: Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195, was added using a Flying Reagent Dispenser to generate a final concentration of 0.75 uM PK11195 inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.36620.69570.44051.11090.5787-0.2699-0.32331.18450.0326-1.0092-1.73120.8267-2.1104-2.3662QC'd by SigmaAldrichInactive0
Inactive0004-0.2849-0.47850.10371.13040.3494-1.2942-2.3851-1.60740.1233-0.8459-1.8941-2.6451-0.2138-0.2849QC'd by SigmaAldrichInactive0
Activator53.984430.302520Partial curve; partial efficacy-4.26772.04370.980730-0.30252.20 0 0 0 0 0 0 0 0 0 0 0 0 0 022.9705-0.53970.19140.0778-0.1425-0.2776-1.9188-0.46281.1362-0.8514-0.42823.186710.348822.9705QC'd by SigmaAldrichActivator27.056334.152540Partial curve; high efficacy-4.56771.47810.9607
Inactive0-7.768610.69720.758810.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.08229.0278.56537.5724.21540.90080.24680.02675.66910.0433-7.0E-4-2.28440.3557-1.0822QC'd by SIGMAInactive0
Activator17.351737.620340Partial curve; high efficacy-4.76073.06540.989337.3935-0.22682.10 0 0 0 0 0 0 0 0 0 0 0 0 0 124.0027-1.13920.1686-0.1252-1.4390.2351-0.49480.65421.28420.05961.310721.815534.209324.0027QC'd by SIGMAActivator4.890445.728181Complete curve; high efficacy-5.31070.70.9547
Inactive00040.5220.023-1.1865-1.4762-0.05160.6407-0.0477-0.5943-1.0553-3.4872-1.7526-1.5011-0.45170.522QC'd by SIGMAInactive0-5.56914.95490.4552
Inactive0-4.27133.29750.65377-0.991840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.71270.1065-2.9589-3.3265-0.1367-0.53720.1194-0.7792-2.1668-3.2131-0.01280.58790.97235.7127QC'd by SigmaAldrichInactive0-4.12134.95490.6439
Inactive0004-4.945-2.5611-5.5604-5.5744-3.7841-2.51970.8205-4.2283-4.7634-6.5963-6.2633-3.1896-5.8718-4.945QC'd by SIGMAInactive0
Inactive0-4.16290.60.42327-1.160340 0 0 0 0 0 0 0 0 0 0 0 0 0 04.3597-0.362-3.0077-3.05030.2438-1.01930.3335-0.4699-1.28130.401-0.46414.3554-0.91184.3597QC'd by SIGMAInactive0-5.51292.33320.8433
Inactive0004-0.70380.0361-3.7089-1.7915-1.25830.16870.69770.1566-2.4696-3.4971-1.51-1.5395-3.4697-0.7038QC'd by SIGMAInactive0
Inactive0004-1.2777-1.6943-2.5955-3.5033-1.64891.17161.2363-2.1104-2.9787-3.3438-1.1157-1.1422-1.1735-1.2777QC'd by SIGMAInactive0
Inactive0004-0.56630.288-2.3707-2.7283-0.63382.07513.38390.0802-2.4707-3.83610.0879-0.2454-2.8389-0.5663QC'd by SIGMAInactive0-4.85851.88510.9504
Inactive0004-1.1005-0.9792-1.7954-2.6037-0.12-0.26040.3413-0.8959-1.9784-3.2297-1.6711-0.0062-3.6975-1.1005QC'd by SIGMAInactive0
Inactive0004-1.2459-4.784-9.0537-2.2125-3.0446-0.91621.9784-0.3992-6.2878-10.5833-9.5972-2.1042-10.227-1.2459QC'd by SIGMAInactive0
Inactive0004-1.0084-1.7104-1.9369-2.0369-1.6802-0.573-0.47480.085-2.3375-4.3727-2.4796-2.5942-2.7424-1.0084QC'd by SIGMAInactive0
Inactive0004-0.9643-2.3604-0.8724-2.1936-0.583-0.2670.1582-0.3325-2.7466-3.9462-1.2392-0.1393-2.9256-0.9643QC'd by SigmaAldrichInactive0
Inactive0004-6.2696-3.3484-4.8795-5.0177-4.9214-3.95680.8092-3.9748-5.0443-6.7588-5.093-3.1627-6.7773-6.2696QC'd by ChemServiceInactive0
Inactive0004-3.7787-1.21870.3496-1.1618-0.178-0.02990.1049-1.7277-1.4204-3.3075-1.8639-0.2976-4.4158-3.7787QC'd by SIGMAInactive0
Inactive0004-5.5543-3.7243-4.3348-6.0183-4.46860.85250.2555-1.1073-5.5639-6.2665-7.6529-4.829-7.4675-5.5543QC'd by SIGMAInactive0
Activator21.579778.216381Complete curve; high efficacy-4.6662.47290.975179.1210.90471.10 0 0 0 0 0 0 0 0 0 0 0 0 0 079.9059-0.6357-0.03330.1670.65420.84030.39860.65146.9793-1.6191.148938.519460.089479.9059QC'd by FisherActivator24.212873.718240Partial curve; high efficacy-4.6161.10.9797
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR224
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195 (final concentration = 0.75 uM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.7001-2.07971.16113.0882-0.077102.1698.77392.9614-2.21710.116619.58354.13960.7001QC'd by ACCInactive0-4.52511.10.5248
Inactive00046.4354-1.02440.0097-0.0933-1.85581.1884-0.92732.35142.15013.76020.1771-1.03550.10946.4354QC'd by ACCInactive0
Inconclusive14.960164.783610Partial curve; high efficacy-4.82511.55790.966665.88741.10382.10 0 0 0 0 0 0 0 0 0 0 0 0 0 064.59921.6564-1.48951.3624-0.33672.53023.07761.2257-1.3673-1.46236.837225.336734.910764.5992QC'd by ACCInconclusive29.849380.826810Partial curve; high efficacy-4.52512.25260.8962
Inactive00047.00811.6498-1.43860.50060.40820.79470.89650.34840.35820.30331.35526.99592.91727.0081QC'd by ACCInactive0
Inactive00043.05635.54866.72620.53512.71380.70682.23040.2851-1.53215.16263.86991.54890.8433.0563QC'd by RTIInactive0
Inactive00040.74666.36313.94348.84614.56211.575.48974.19182.16295.86320.50451.34453.99310.7466QC'd by RTIInactive0
Inactive00040.67381.12332.28591.01811.5966-0.43621.77940.2945-1.37111.71640.89490.65662.50770.6738QC'd by RTIInactive0
Inactive00041.00343.59883.74021.61832.4828-24.1996-11.8417-15.26063.54570.8131-0.0321-11.9734-1.31061.0034QC'd by RTIInactive0
Inactive0-4.18464.95490.9125-10.752.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.31021.06850.91324.13362.67391.81972.26761.87431.57794.70882.78081.3363-11.4583-9.3102QC'd by RTIInactive0-3.83464.50450.8486
Inactive0-4.15534.95490.6213-8.5472540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7063.03746.28947.39888.83679.30074.16635.48521.16012.64973.10975.62653.3473-6.706QC'd by RTIInactive0-4.50531.13410.921
Inactive0-4.07872.90230.7611-27.65215.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.71016.68477.71693.3955.081315.63232.80533.07480.28617.9345.15692.3389-1.44-19.7101QC'd by RTICytotoxic74.351457.123720Single point of activity-4.12872.90230.9124
Cytotoxic57.09755.000921Partial curve; partial efficacy-4.24343.57220.9446-54.11980.881-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.68171.44960.64610.87374.0413-0.6397-8.70514.50811.25313.61011.83811.5671-14.0711-46.6817QC'd by RTICytotoxic57.09772.527141Partial curve; partial efficacy-4.24342.35310.9803
Cytotoxic69.1718108.736442Partial curve; high efficacy-4.16012.63840.9717-107.06951.6669-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.11334.12134.26247.21762.32561.1447-8.56171.58873.20240.90921.8827-6.6983-25.0645-81.1133QC'd by RTICytotoxic54.9451118.001241Partial curve; high efficacy-4.26012.12110.9982
Inactive00041.23831.33150.88153.39274.07264.82921.16914.05412.98531.32630.32392.28032.47551.2383QC'd by RTIInactive0
Cytotoxic62.612238.428920Partial curve; partial efficacy; poor fit-4.20332.53340.9423-35.92892.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.44074.56793.2733.0004-0.82787.03151.32971.03340.94391.5864-0.53831.1816-10.0481-27.4407QC'd by RTICytotoxic55.803256.613421Partial curve; partial efficacy-4.25332.53340.9455
Cytotoxic34.636240.085420Partial curve; partial efficacy-4.46052.78680.9485-35.58544.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-37.55547.86573.08136.25493.50321.57814.64299.84995.08361.63343.0637-4.2032-21.4975-37.5554QC'd by RTICytotoxic48.92563.310741Partial curve; partial efficacy-4.31052.40640.966
Inactive0-4.95263.51170.4728-12.1793140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.88662.10451.60872.2705-1.9686-0.7779-1.63741.02741.49992.1762.5-23.0661-2.7817-0.8866QC'd by RTIInactive0-4.15262.63840.6052
Inactive0004-2.84033.5493.05938.34540.08545.4167-0.89290.03223.37180.29422.8684-1.08252.444-2.8403QC'd by RTIInactive0-4.09594.95490.8672
Inactive00040.57120.96791.09642.61560.08615.51343.14970.57852.83021.933.1832-1.67453.16860.5712QC'd by RTIInactive0
Inactive0-4.51414.95490.6339-9.2283240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.63681.3480.78612.61030.0177-0.69933.3843-0.57490.00933.38765.62053.6707-9.3569-0.6368QC'd by RTICytotoxic68.537737.040120Partial curve; partial efficacy; poor fit-4.16412.90230.9194
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:HIV-1 Vif
External ID: HIV1-VIF_MS
Protocol: The assay protocol for screening and testing compounds included plating a mixture of GST-Vif "donor" protein and bio-A3G "acceptor" peptide with test compounds in white, non-binding surface 1536-well plates. LANCE reagents were purchased from PerkinElmer. Briefly, 15nM GST-Vif protein was added to the assay plate containing test compounds. Following a 30 minute incubation, 500 nM bio-A3G peptide was added. Following another 30 minute incubation, 2 nM Eu-labeled anti-GST and 50 nM streptavidin-Ulight detection reagents were added to the assay plate and incubated for 1 hour. After the final incubation, TR-FRET signals were measured using an Envision microplate reader with excitation at 340 nm and emission at 615 and 665 nm. The emission at 615 nm from Eu-labeled anti-GST induces emission at 665 nm from Ulight conjugated to streptavidin when the two molecules are in close proximity, resulting in a FRET signal. GST-Vif binding to the bio-A3G peptide produced a significant increase in the FRET signal over background levels measured in the presence of GST.

To evaluate the screening results each plate included negative and positive controls. Negative control wells included all assay components in the absence of an inhibitor and positive control wells included all assay components with GST-Vif 1-94 protein replaced by GST protein. Percent inhibition was determined as: 100*((Test Compound Signal - Median Negative Control Signal)/(Median Positive Control Signal - Median Negative Control Signal)).
Comment: In the Dose Response, compounds that showed >30% inhibition for at least one concentration were considered potentially active, however some compounds were tested in dose response on more than one occasion. If conflicting results were observed, the compound was deemed "inconclusive". Only compounds that consistently showed activity across all test dates were labeled "Active". Any compounds in the primary screen active range that were not available for testing in dose response were labeled "Inconslusive".
The following tiered system has been implemented at Southern Research Institute for use with the PubChem Score. Compounds in the primary screen are scored on a scale of 0-40 based on inhibitory activity where a score of 40 corresponds to 100% inhibition. In the confirmatory dose response screen, active compounds were scored on a scale of 41-80 based on the average IC50 result, inconclusive compounds were given the lowest confirmatory score of 41, and compounds that were tested and did not confirm as actives were given the score 0.
Average IC50 ModifierAverage IC50IC50 Modifier Rep1IC50 Rep 1IC50 Modifier Rep2IC50 Rep2IC50 Modifier Rep3IC50 Rep3StDev IC50 Rep1IC50 Hill Slope Rep1IC50 NormChi2 Rep1StDev IC50 Rep2IC50 Hill Slope Rep2IC50 NormChi2 Rep2StDev IC50 Rep3IC50 Hill Slope Rep3IC50 NormChi2 Rep3Pct Inhibition @ 100 uM Rep1Pct Inhibition @ 50 uM Rep1Pct Inhibition @ 25 uM Rep1Pct Inhibition @ 12.5 uM Rep1Pct Inhibition @ 6.25 uM Rep1Pct Inhibition @ 3.125 uM Rep1Pct Inhibition @ 1.563 uM Rep1Pct Inhibition @ 0.781 uM Rep1Pct Inhibition @ 0.391 uM Rep1Pct Inhibition @ 0.195 uM Rep1Pct Inhibition @ 100 uM Rep2Pct Inhibition @ 50 uM Rep2Pct Inhibition @ 25 uM Rep2Pct Inhibition @ 12.5 uM Rep2Pct Inhibition @ 6.25 uM Rep2Pct Inhibition @ 3.125 uM Rep2Pct Inhibition @ 1.563 uM Rep2Pct Inhibition @ 0.781 uM Rep2Pct Inhibition @ 0.391 uM Rep2Pct Inhibition @ 0.195 uM Rep2Pct Inhibition @ 100 uM Rep3Pct Inhibition @ 50 uM Rep3Pct Inhibition @ 25 uM Rep3Pct Inhibition @ 12.5 uM Rep3Pct Inhibition @ 6.25 uM Rep3Pct Inhibition @ 3.125 uM Rep3Pct Inhibition @ 1.563 uM Rep3Pct Inhibition @ 0.781 uM Rep3Pct Inhibition @ 0.391 uM Rep3Pct Inhibition @ 0.195 uM Rep3Max Inhibition Rep1Conc @ Max Inhibition Rep1Max Inhibition Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR404
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO (final concentration = 50 nM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-1.2885-8.2133-8.16350-7.1502-6.0582-1.0685-6.9497-7.74221.4318-0.484-9.89-5.9739-1.2885QC'd by LightBiologicalsInactive0
Inactive0-4.21374.50450.3794-2.0019-11.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.2267-13.6359-11.5589-12.427-11.9862-12.3014-2.0849-11.776-12.2205-11.2807-10.5655-12.6043-10.0799-3.2267QC'd by SIGMAInactive0
Inactive0004-18.8355-16.5392-15.7843-14.6365-14.6435-14.8247-15.1826-17.2997-17.0567-15.571-15.4498-16.8771-18.7769-18.8355QC'd by SIGMAInactive0
Cytotoxic61.130668.499141Partial curve; partial efficacy-4.21373.57220.9855-82.6763-14.1772-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.8305-13.3313-15.7246-16.9851-15.1291-16.6431-12.0943-15.0603-13.2228-10.6311-12.392-15.5076-28.0786-69.8305QC'd by SIGMACytotoxic61.130688.918141Partial curve; high efficacy-4.21372.47290.9648
Inactive0004-9.4937-8.4802-2.4154-6.8019-7.6968-8.7013-4.9931-5.9136-8.161-5.4834-5.5854-7.8666-8.6242-9.4937QC'd by LightBiologicalsInactive0-8.06374.95490.5744
Inactive0-4.21373.29750.784-19.65540.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.54620.30110.54811.68972.3515-1.76286.6762-2.18030.3036-2.6294-0.6711-0.2348-3.468-15.5462QC'd by SIGMAInactive0-4.21370.40.6227
Inactive0004-0.8117-4.0669-9.8967-11.0574-6.4365-5.9282-6.3535-7.6972-5.2867-9.8338-1.3993-0.8947-7.6295-0.8117QC'd by SIGMAInactive0
Cytotoxic61.503855.678321Partial curve; partial efficacy-4.21113.990.9569-57.7149-2.0366-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.64770.26981.6175-2.9758-3.96481.7183-4.47090.3089-5.9715-1.9196-1.5152-1.5012-11.187-48.6477QC'd by ChemServiceInactive0-4.21114.95490.8972
Inactive0-4.11374.95490.6896-23.3009040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.75070.5104-1.55631.8378-3.19332.5092-0.693-8.08051.92620.04853.9244-2.18611.6782-17.7507QC'd by SIGMAInactive0-4.21374.0950.6638
Cytotoxic60.5715107.680742Partial curve; high efficacy-4.21771.86170.9797-127.4822-19.8016-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.5775-19.6657-16.6526-20.809-21.6607-19.7704-14.2217-18.8965-22.5975-21.7271-20.6249-34.5795-53.8367-96.5775QC'd by EPACytotoxic42.8813102.238741Partial curve; high efficacy-4.36771.96730.9874
Cytotoxic34.201550.561640Partial curve; partial efficacy-4.4661.46410.9284-54.0991-3.5375-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.0918-2.7848-1.0730.0864-3.1155-8.38860.2833-5.2666-5.937-8.2702-10.3681-18.193-25.3466-50.0918QC'd by CrescentCytotoxic30.482144.89120Partial curve; partial efficacy-4.5161.47810.9399
Inactive0-3.96370.80.6909-31.6-3.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23-4.3769-2.78840.141-3.552-4.8242-6.7976-4.9877-2.8309-6.1986-3.8792-6.6066-8.0591-23QC'd by Sigma DiscoveryCPRCytotoxic61.130637.500120Single point of activity-4.21373.62720.9475
Inactive00042.7896-2.2890.3967-3.4023-0.5931-3.73261.98680.266-0.04370.42130.10770.45910.0122.7896QC'd by SIGMAInactive0
Inactive00040.26690.57262.32333.2007-0.42921.18692.47032.29592.39542.45931.99820.27692.75730.2669QC'd by SIGMAInactive0
Inactive00040.15290.81242.78170.7373.17970.4171.1829-3.29880.4225-0.650.0220.90230.99470.1529QC'd by SIGMAInactive0
Inactive0-4.11374.95490.7475-10.5412240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11761.66523.16792.25360.69250.89822.26921.6541.01862.7189-0.12983.29222.2598-7.1176QC'd by SIGMAInactive0-4.56374.50450.3801
Inactive0004-3.2742-0.57391.18390.6992-0.1356-0.9956-3.9472-0.31020.02640.46931.55660.2082-3.8232-3.2742QC'd by SIGMAInactive0
Inactive0004-0.7927-6.5931-0.004-0.87430.5458-3.7497-2.0427-2.5866-3.6954-3.9867-18.7143-2.0222.5912-0.7927QC'd by SIGMAInactive0
Inactive0004-13.9982-8.8449-6.7122-3.2554-8.551-4.4661-2.4558-5.8647-10.1231-5.4289-3.8809-5.1227-8.4815-13.9982QC'd by SIGMAInactive0
Inactive0004-0.2549-3.2147-2.0568-1.3426-0.21941.32071.5504-1.1495-1.6104-0.5283-1.0103-2.0348-1.3745-0.2549QC'd by LightBiologicalsInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC875
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.3468-0.10070.0358-0.33470.23222.509-4.5860.2540.48071.16460.75384.1574-4.8525-0.3468QC'd by SIGMAInactive0
Inactive0004-3.3197-5.6995-7.8071-6.0662-4.9082-8.0484-7.708-4.8984-5.8365-2.5967-1.1821-5.7986-3.0963-3.3197QC'd by SigmaAldrichInactive0
Inactive00041.84520.97091.1435-0.24060.0731-0.12051.2062-0.18330.0921.20720.47061.31020.49521.8452QC'd by SIGMAInactive0-4.01730.70.5777
Inhibitor34.131725.96160Partial curve; partial efficacy-4.46682.33320.9617-25.96160-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.9681.69630.1516-1.09160.4925-0.73560.52772.66582.0E-4-2.8872-3.0257-4.5147-15.6179-24.968QC'd by SIGMAInhibitor48.212321.71050Partial curve; partial efficacy-4.31681.82650.8711
Inactive00041.39531.94521.30180.9104-0.31670.42261.07071.9713-0.37872.93970.83462.12710.21931.3953QC'd by SigmaAldrichInactive0
Inactive0-4.06334.95490.4301-7.0921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.24341.0247-0.6334-0.0593-0.5529-0.870.3563-3.05990.0772-2.04451.2375-0.9179-0.0839-4.2434QC'd by SIGMAInactive0-4.31333.51170.5308
Inactive0-5.75854.95490.3744-2.0452140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.39762.44991.9442.7333-0.72910.18521.02430.39980.1524-5.0377-4.45790.10940.3382-0.3976QC'd by SigmaAldrichInactive0
Inactive00044.02841.30910.502-2.96730.6114-3.0343-5.43691.67780.79992.43120.8290.0491.04384.0284QC'd by Alfa AesarInactive0
Inactive0-5.26464.95490.4346-2.0801140 0 0 0 0 0 0 0 0 0 0 0 0 0 11.98340.29922.4906-0.22330.3752.7141.88570.4384-0.23811.8609-3.01220.5146-3.40011.9834QC'd by SIGMAInactive0
Inactive00042.63350.03471.26840.123-0.3218-0.7076-0.30731.1541.4491.46540.89010.0407-0.34962.6335QC'd by SIGMAInactive0
Inactive0-4.09724.95490.45685-0.300340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4899-1.55050.48970.6246-0.8749-0.70910.3983-0.38271.38450.1489-2.3336-0.5514-0.29293.4899QC'd by SigmaAldrichInactive0
Activator42.573923.761320Partial curve; partial efficacy-4.37091.46410.9148240.23872.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.55410.00531.42-0.16480.3750.50141.6438-0.125-0.76833.78914.61832.97299.933520.5541QC'd by SIGMAActivator60.13733020Partial curve; partial efficacy-4.22092.53340.9705
Inactive00042.55290.4063-0.01020.18952.3191-1.84951.7387-1.9418-1.54353.99270.02911.34360.7672.5529QC'd by SIGMAInactive0-8.36331.28760.3456
Inactive00041.41240.5842.30430.55631.00343.2421-0.03291.7832-2.03062.37860.03731.3846-0.48531.4124QC'd by ChemServiceInactive0
Inactive00043.2372-0.06260.30520.0902-0.17460.25520.3996-0.2881.25733.132-0.27620.86140.24633.2372QC'd by SIGMAInactive0
Inactive00042.54410.50790.20260.3539-0.13770.985-0.3504-1.23841.32581.2338-2.15810.15631.45512.5441QC'd by SIGMAInactive0
Inactive0-4.17223.67720.6648-5.8375140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.03120.75431.06750.67620.09292.30830.48760.50432.7882-0.24950.6636-0.05580.1164-4.0312QC'd by City ChemicalInactive0
Inhibitor17.334135.94590Complete curve; high efficacy-4.76113.1320.981-35.94590-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.7947-1.1822-0.3985-2.19492.5399-2.8881-1.15330.37421.44382.4728-1.8207-20.2287-32.2128-36.7947QC'd by InterchemInhibitor15.44939.10510Complete curve; high efficacy-4.81112.33320.9633
Inactive0-4.17994.0950.4925-4.84510.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.62090.76960.04541.12750.09010.13020.2945-0.00821.2284-0.19962.4956-2.29050.011-3.6209QC'd by SIGMAInhibitor46.785537.00050Partial curve; partial efficacy-4.32991.69240.9362
Inactive0004-3.6855-2.20722.44460.09531.2718-2.0196-1.5529-1.1351-0.9412-2.5691-0.9983-2.4138-2.9275-3.6855QC'd by SIGMAActivator5.431631.161281Complete curve; high efficacy-5.26511.34430.9707
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TSHR942
Protocol: Tox21 Assay Protocol Summary:

TSHR-Hek293 cells were dispensed at 800 cells/4uL/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool, followed by 1 ul medium containing Ro20-1724. The plates were incubated at room temperature for 30 min. 2.5 ul/well of cAMP-d2 and 2.5ul/well of anti-cAMP-cryptate was added respectively into the assay plates using a Flying Reagent Dispenser. After 1 hr incubation at room temperature, the fluorescence intensity in the plates was measured using an Envision plate reader. Each test compound was measured at 15 concentrations and in triplicates.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W615-Activity_Score-Replicate_1W615-Curve_Description-Replicate_1W615-Fit_LogAC50-Replicate_1W615-Fit_HillSlope-Replicate_1W615-Fit_R2-Replicate_1W615-Fit_InfiniteActivity-Replicate_1W615-Fit_ZeroActivity-Replicate_1W615-Fit_CurveClass-Replicate_1W615-Excluded_Points-Replicate_1W615-Max_Response-Replicate_1W615-Activity at 0.0000060039 uM-Replicate_1W615-Activity at 0.0000137707 uM-Replicate_1W615-Activity at 0.0000545120 uM-Replicate_1W615-Activity at 0.0001296300 uM-Replicate_1W615-Activity at 0.0003002588 uM-Replicate_1W615-Activity at 0.0006197232 uM-Replicate_1W615-Activity at 0.00170 uM-Replicate_1W615-Activity at 0.00522 uM-Replicate_1W615-Activity at 0.013 uM-Replicate_1W615-Activity at 0.030 uM-Replicate_1W615-Activity at 0.068 uM-Replicate_1W615-Activity at 0.153 uM-Replicate_1W615-Activity at 0.349 uM-Replicate_1W615-Activity at 1.067 uM-Replicate_1W615-Activity at 3.267 uM-Replicate_1W615-Activity at 8.386 uM-Replicate_1W615-Activity at 18.95 uM-Replicate_1W615-Activity at 42.46 uM-Replicate_1W615-Activity at 92.41 uM-Replicate_1W615-Activity at 240.3 uM-Replicate_1W615-Activity at 872.4 uM-Replicate_1W615-Activity at 1849.0 uM-Replicate_1W615-Activity at 4135.0 uM-Replicate_1W615-Activity at 9246.0 uM-Replicate_1W615-Activity at 20670.0 uM-Replicate_1W615-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100046.71165.91411.01090.48573.26231.84362.00641.99435.44978.12683.9593.84525.64976.711610004-2.748
Inactive100041.15973.45360.9481-0.52418.4135-5.3381-0.2037-1.12098.426911.44892.56851.52615.51131.159710004-0.2798
Inactive1000413.619319.24979.80112.092519.851720.559717.738615.489515.20168.327325.730421.994613.226513.619310004-8.0616
Inactive10004-0.01774.084512.92615.3982.40380.8257.68639.482714.70655.1151-0.75927.9425-1.263-0.017710004-2.1171
Inactive100043.1252.35685.09388.475210.98810.10777.68738.07633.86263.49345.21091.85468.95053.12510004-15.6867
Inactive100047.46870.77720.070411.33447.3155.46854.97583.73919.3253-1.65574.71633.480410.62097.468710-8.61680.30.3731-11.65381840 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1384
Inactive10-5.36373.51170.3912-2-8.811940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9865-8.0324-8.6353-2.0989-6.6589-13.3952-12.0664-9.0355-11.3374-6.2204-1.73390.0195-5.6888-2.986510004-24.5166
Activator37.79197.19310004-6.7723-1.27140.9157-4.0255-10.6032-5.96680.5902-3.4901-1.7017-13.963-2.6223-0.0117-2.2437-6.77230Partial curve; high efficacy-4.42261.22210.920696.8641-0.32892.10 0 0 0 0 0 0 0 0 0 0 0 0 0 081.1085
Inactive100041.5703-3.83490.9073-2.0903-1.2647-1.4311-3.4337-4.0019-0.4467-1.59621.99851.4791-3.3903-4.9221.570310004-4.9352
Inconclusive10004-0.6217-8.1939-9.7496-1.3131-1.96560.67370.907-13.3517-7.4235-3.3313-2.5924-1.9513-5.0812-0.62170Partial curve; partial efficacy; poor fit-4.51371.62590.7426-35.2959-4-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.4966
Inactive10004-0.97-4.3623-1.46539.6687-8.1041-8.3111-5.9686-3.301-4.21888.9934-5.42630-0.6903-0.9710004-9.314
Inactive10004-1.4457-6.89480.2171-2.9459-4.0435-7.3456-1.1919-9.5752-2.6175-0.3368-10.17-0.6414-0.3902-1.445710004-2.246
Activator9.678780.70610004-5.3519-9.0236-6.6327-5.8557-0.1803-16.2183-5.9643-10.6841-5.3049-7.3617-3.4598-16.9691-11.695-5.35190Partial curve; high efficacy-5.01420.80.925776.7855-3.92052.10 0 0 0 0 0 1 0 0 0 0 0 0 0 075.366
Inactive10004-2.6023-5.1436-20.2543-4.2156-18.6587-1.1774-0.484-24.4038-1.4626-19.5587-5.8609-4.7343-6.9928-2.602310-4.16370.90.3781-32.45411.727340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2572
Inactive10-4.61370.90.4124-15.1446-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.347-0.3142-1.0420.9937-0.4332-5.17271.7846-9.5432-1.6937-2.2733-1.8768-12.2038-8.3511-0.347100041.5347
Inhibitor24.336570.80710004-0.78071.9061-0.7815-4.8851-12.66.6198-2.75363.05454.79781.16051.40111.6918-6.1939-0.78070Partial curve; partial efficacy-4.61371.69240.6988-64.3076.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-29.6108
Inactive10004-0.90493.2372.47662.64980.4207-1.39261.0889-11.66593.0536-1.96911.06293.9096-0.09-0.904910-6.26374.95490.42258.5-0.163240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.6214
Inactive10-4.66371.46410.3698-14.6386-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.0234-8.0187-2.80042.58961.4724-2.46990.0707-3.28221.0981-1.2965-10.7454-0.5498-16.3655-11.023410004-27.7999
Inactive10-6.56424.95490.44474.5-3.852440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.6033-4.33852.27942.7066-14.0436-0.8758-9.51473.77765.08233.93465.49423.25690.88475.603310-6.76424.95490.3433-3.052140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.4886
Inhibitor18.49830.91151000413.22156.882221.7764.66487.65575.4813.49695.24837.72715.712213.43636.7754-1.020413.22150Partial curve; partial efficacy; poor fit-4.73294.95490.5896-30.65330.2582-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.5807
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC363
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197192 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.073 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 237.6 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.75414.95490.42033-4.98140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.9106-3.9228-5.9903-6.0515-1.4717-5.2912-7.602-5.9977-2.42-5.7364-8.2934-0.25662.9408-4.9106QC'd by SigmaAldrichInactive0
Inactive0004-3.3812-1.5662-16.55440.4975-4.09261.5304-12.9724-8.9269-1.91620.6198-11.0605-9.0324-13.3792-3.3812QC'd by SIGMAInactive0
Inactive00041.5277-10.1634-0.00874.0005-6.6661-6.69563.5741-1.09852.27453.2409-13.4326-7.2215-7.42071.5277QC'd by SigmaAldrichInactive0
Inactive0004-1.017-0.1246-23.0301-16.6405-6.1553-10.2548-6.5018-9.7542-2.401-3.4974.2117-8.21190.1193-1.017QC'd by SigmaAldrichInactive0-5.65984.95490.539
Inactive00043.38271.7071.93473.1752-3.8498-3.73072.23732.339-0.9899-3.4194-1.9669-9.73383.77663.3827QC'd by SIGMAInactive0
Inactive0004-0.73285.5587.8092.5786-0.96210.07372.9401-0.38870.14421.36820.83672.63761.7298-0.7328QC'd by SigmaAldrichInactive0
Inactive00042.35882.51021.81950.59232.94893.56280.6572-0.3826-0.85440.17520.73831.72051.81952.3588QC'd by Io-li-tecInactive0
Inactive00041.38781.00940.6532-1.03560.36512.28341.3107-16.37711.71522.1357-0.1164-0.65752.02321.3878QC'd by Io-li-tecInactive0
Inactive00045.46932.7258-1.71972.3804-20.79223.17021.6326-1.2539-13.72260.20822.47040.50210.58075.4693QC'd by SIGMAInactive0-5.85983.06540.6429
Inactive0-4.16644.0450.6851-12.45790.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.54830.2178-0.2309-0.79570.51171.13541.4003-0.03322.55783.2818-3.286-1.4703-0.7627-9.5483QC'd by SIGMAInactive0-4.36641.98870.8468
Inconclusive23.990430.144810Partial curve; partial efficacy; poor fit-4.620.70.747630-0.14482.40 0 0 0 0 0 0 0 0 0 0 0 0 0 022.60371.2906-5.817-1.8818-7.2041.07217.41797.545.08272.19837.159913.888719.365422.6037QC'd by SIGMAInactive0-4.120.50.4
Inactive00042.59482.69211.2072-3.7186-4.66812.76633.94650.38173.5477-0.23396.89892.65815.70112.5948QC'd by AcrosInactive0
Inactive0-4.19134.0450.813213-1.521440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5641-2.86591.25950.2725-1.1592-2.4294-2.1941.7532-2.4893-1.6357-0.1925-1.74781.073610.5641QC'd by SIGMAInactive0
Inactive00047.9141-1.9689-2.253-4.53782.2968-12.15473.36423.88694.99273.8103-8.57025.75174.7237.9141QC'd by SIGMAInactive0
Cytotoxic30.357783.203640Partial curve; high efficacy-4.51771.55790.9633-85.4248-2.2213-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.09710.1445-3.4687-6.33-5.4346-2.1394-5.5181-4.45781.539-0.7887-20.6233-25.9409-48.5781-79.0971QC'd by SIGMACytotoxic60.571591.352241Partial curve; high efficacy-4.21771.3310.9211
Inactive0-4.11374.95490.508311-1.19640 0 0 0 0 0 0 0 0 0 0 0 0 0 07.6371-0.9966-6.4133-1.62961.9829-2.5154-0.6080.0257-0.63170.3616-2.9777-3.0149-0.89117.6371QC'd by SIGMAInactive0
Cytotoxic69.777181.308620Single point of activity-4.15634.95490.9502-84.9425-3.6339-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.79571.365-8.0975-1.71050.6639-11.5921-1.7071-5.2425-4.18560.7387-7.358-7.5217-8.401-69.7957QC'd by SigmaAldrichCytotoxic69.777178.320620Single point of activity-4.15634.95490.9859
Inactive0004-13.1552-4.8346-4.34493.2135-7.58344.6528-8.09981.1002-3.0242.43910.6845-2.3657-3.4277-13.1552QC'd by SigmaAldrichInactive0-6.31074.95490.4218
Inactive0004-22.127-12.1698-7.5453-6.5016-5.9755-2.61933.5381-1.3673-14.7241-1.0064-4.7639-6.1963-2.5303-22.127QC'd by InterchemCytotoxic69.567322.86820Single point of activity-4.15764.95490.8014
Inactive0004-5.0254-5.9486-2.7845-5.6405-2.1794-5.01680.8851-0.4331-4.3384-8.3171-7.9408-6.7025-12.8316-5.0254QC'd by SigmaAldrichInactive0-7.15934.95490.3077
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC907
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-7.31554.95490.55256-10.506740 0 0 0 0 0 0 0 0 0 0 0 0 0 01.801-5.491-7.986-20.8389-13.33246.28051.45194.0156-1.49715.503217.479718.13128.25281.801QC'd by SIGMAInactive0
Inactive0-5.55854.95490.414910-3.634840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.8804-1.78583.6024-6.131-18.86241.55921.63912.0415-8.03311.875915.20442.08323.413816.8804QC'd by SigmaAldrichInactive0
Inactive00048.71311.8866-1.71662.80311.5009-12.00410.7575.6763-5.58230.5326-1.94871.56463.21748.7131QC'd by SIGMAInactive0
Inactive00041.38123.09412.98235.29743.65263.73992.58423.992310.1669.33368.2397-3.59293.03941.3812QC'd by SigmaAldrichInactive0
Inactive0-5.21022.18760.708121.3899-4.687740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7888-7.3321-7.2161-5.9695-3.47354.0032.56842.7648-12.70273.788413.36314.120524.94961.7888QC'd by ChemServiceInactive0
Inhibitor19.2133337.934344Partial curve; high efficacy-4.71640.50.8478-333.03594.8984-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-252.2999-0.7118-0.9263-5.706-0.121-7.8262-19.3177-30.6174-72.0512-141.5323-123.9442-69.283-223.2304-252.2999QC'd by CytecInhibitor0.541591.790188Complete curve; high efficacy-6.26642.24810.8093
Inactive000416.32936.1544-16.59613.5287-3.494911.62383.5327-5.0571-6.0458-18.6327-4.28816.37352.673916.3293QC'd by SigmaAldrichInactive0
Inactive0-4.55674.95490.4793-23.369-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.59612.49199.058-0.042.1764-12.5203-9.6302-4.47431.7432-2.4338-7.1101-1.5691-22.8075-11.5961QC'd by SIGMAInactive0
Inactive0-4.12184.95490.449526-2.605540 0 0 0 0 0 0 0 0 0 0 0 0 0 020.619-2.119910.8862-0.6531.1832-6.5161-12.30681.6601-2.4009-5.2525-1.0688-1.081-15.921220.619QC'd by SigmaAldrichInactive0
Inhibitor39.277963.752610Partial curve; partial efficacy; poor fit-4.405910.5919-69.8334-6.0808-2.40 0 0 0 0 0 0 1 0 0 0 0 0 0 0-50.3057-6.0808-3.833-13.0728-18.3166-16.1035-3.3344-39.328-14.4105-11.2535-19.6606-3.471-55.4233-50.3057QC'd by SigmaAldrichInactive0
Inactive0-4.30931.3310.825428440 0 0 0 0 0 0 0 0 0 0 0 0 0 021.58514.24835.69328.56476.9910.88430.9534.82571.8614.69056.67246.912515.164121.5851QC'd by SIGMAInactive0-8.80934.95490.3266
Inactive0-7.01910.20.430317.5-12.668140 0 0 0 0 0 0 0 0 0 0 0 0 0 010.0881-3.90832.3807-10.14017.97570.438612.25-0.05663.12176.070511.49712.456319.720110.0881QC'd by SigmaAldrichInactive0
Inactive0-4.86681.98870.55326.9348-3.820740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.3376-7.6928-0.53331.7983-4.65540.58472.4554-8.8369-11.17517.03152.967515.389924.36441.3376QC'd by ChemServiceInactive0
Inactive0-4.13584.95490.546-35.94241.49140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.27790.98835.171-5.248411.3338-0.09311.90132.24583.6879-3.4241-9.6853-6.06656.4942-28.2779QC'd by ChemServiceInactive0-5.88580.30.6749
Activator59.332235.05150Single point of activity-4.22673.990.833838.53.448530 0 0 0 0 0 0 0 0 0 0 0 0 0 033.30954.22966.671610.30334.46525.68211.882812.80621.179613.60763.64714.72757.038733.3095QC'd by SIGMAInactive0
Inactive0004-18.3735-7.17083.2132-14.43274.2935-17.38060.81161.09940.61580.3307-12.4961.5395-1.1314-18.3735QC'd by SIGMAInactive0
Inactive0-4.86151.88510.4207-25.5319-140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5765-5.8516-15.33963.9162-1.52163.46663.89890.63135.3836-14.6469-0.8588-20.291-21.276612.5765QC'd by SIGMAInactive0-4.86150.30.6157
Activator69.3576284.63330Partial curve; high efficacy-4.15894.95490.9582290.23735.60392.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0239.46977.4741-0.21950.527-1.08286.48486.11090.902420.65386.373815.29646.5792-2.3841239.4697QC'd by SIGMAActivator69.3576259.95740Single point of activity-4.15894.95490.9713
Inactive0-8.81644.95490.4623-26.538540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.1952-9.4853-0.73863.1728-13.46198.36624.0971-0.382711.06927.1292-0.8452-3.79372.19738.1952QC'd by SIGMAInactive0-4.11644.95490.4257
Inactive0-5.16024.95490.810517-5.339140 0 0 0 0 0 0 0 0 0 0 0 0 0 020.0371-5.3775-5.3595-10.6992-6.74984.98782.3993-9.0254-6.8107-9.764111.372511.406218.847720.0371QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HIF170
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000049734 uM-Replicate_1W530-Activity at 0.0000113459 uM-Replicate_1W530-Activity at 0.0000446985 uM-Replicate_1W530-Activity at 0.0001080938 uM-Replicate_1W530-Activity at 0.0002492385 uM-Replicate_1W530-Activity at 0.0005106135 uM-Replicate_1W530-Activity at 0.00140 uM-Replicate_1W530-Activity at 0.00426 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.057 uM-Replicate_1W530-Activity at 0.128 uM-Replicate_1W530-Activity at 0.291 uM-Replicate_1W530-Activity at 0.878 uM-Replicate_1W530-Activity at 2.670 uM-Replicate_1W530-Activity at 7.009 uM-Replicate_1W530-Activity at 15.84 uM-Replicate_1W530-Activity at 35.48 uM-Replicate_1W530-Activity at 76.84 uM-Replicate_1W530-Activity at 198.7 uM-Replicate_1W530-Activity at 725.3 uM-Replicate_1W530-Activity at 1537.0 uM-Replicate_1W530-Activity at 3438.0 uM-Replicate_1W530-Activity at 7687.0 uM-Replicate_1W530-Activity at 17190.0 uM-Replicate_1W530-Activity at 38440.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-3.6553-0.9893-3.5818-1.17650.2463-0.2234-0.9145-0.01270.2733-0.26810.30620.5194-3.3182-3.655310004-0.2957
Inactive100041.82260.0462.81770.4783.4369-1.20180.3150.57551.36561.70740.581-1.5460.3161.822610004-0.7107
Inconclusive21.313826.487710Partial curve; partial efficacy-4.67131.88510.9421270.51232.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.1544-1.23981.60671.0591-0.37590.27121.8173-0.79810.55232.50490.08824.576511.091520.154410004-3.7146
Inactive10-5.27134.95490.37923.5-0.39640 0 0 0 0 0 0 0 0 0 0 0 0 0 11.11-0.22040.39841.729-2.1419-1.0363-2.83-0.8962-0.41591.0879-0.28773.13323.13221.11100040.2226
Inconclusive20.596119.464310Partial curve; partial efficacy; poor fit-4.68620.20.358-21.5626-2.0984-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.687-4.9503-10.9522-8.9046-1.6211-0.082-5.788-7.8292-6.4939-9.6741-10.0897-14.9287-16.3022-10.68710004-0.8617
Inconclusive3.023217.722210Partial curve; partial efficacy; poor fit-5.51950.40.6216-23.6128-5.8906-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.9702-7.4334-8.7638-12.1242-3.2422-6.6164-6.414-17.1247-10.8286-15.8444-16.4368-20.094-16.7283-12.970210-8.96954.95490.78710.9737.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1086
Inactive100041.5223-1.7357-0.7438-3.6994-0.395-0.29530.4241-3.0256-2.7235-1.8125-1.1286-0.6724-2.7321.522310004-0.2476
Inactive10004-12.8642-6.1115-9.8495-9.2614-3.1038-3.26460.1035-13.4348-10.1594-9.5645-9.6545-16.3803-14.6367-12.8642100040.3025
Inactive10004-0.0604-2.1693-3.4849-0.6126-2.4801-0.7035-2.75370.0219-1.0218-2.56510.0598-5.2827-0.7625-0.0604100040.3359
Inactive10004-3.46910.5975-4.6703-1.7651-0.7229-3.1804-0.9474-1.3234-0.6065-3.7492-3.479-2.4871-0.3194-3.4691100042.2474
Inactive10-6.7751.10.3519-3.6702-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9024-0.0717-0.9296-1.0266-2.29810.7439-3.8561-0.582-2.5247-7.2252-4.5423-1.3126-2.0748-0.9024100043.0923
Inactive10004-9.8666-1.1348-6.2751-5.2223-1.99990.0905-0.7847-3.2022-1.5132-2.9373-4.0064-4.484-6.056-9.8666100041.8718
Inactive10004-8.9364-1.2425-5.5217-3.44221.1273-2.75941.619-1.0059-2.884-3.0865-4.52-3.9722-9.247-8.936410-4.40651.66040.93388.5140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1016
Inconclusive10.276517.852710Partial curve; partial efficacy; poor fit-4.98820.60.445-20.2075-2.3548-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.1898-3.0172-8.3806-7.0506-3.6035-1.3277-0.2956-8.0513-1.2813-9.1424-7.6654-15.1729-14.3238-7.189810004-1.0635
Inactive10-5.74990.60.6027-15.0694-4.122240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8447-4.9088-8.1722-1.7685-3.24-3.1309-4.6399-11.5479-7.3956-9.2891-12.3039-14.1602-14.2245-11.8447100043.318
Inconclusive4.395417.188910Complete curve; partial efficacy; poor fit-5.3570.80.5163-25.9259-8.737-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.6982-6.7445-16.6319-7.1908-5.879-5.5985-3.9475-15.8575-10.3684-14.7455-20.4174-24.9382-21.2805-18.6982100044.3064
Inactive10004-13.1388-3.3075-12.7272-9.0493-9.8786-7.1457-2.8049-12.1577-10.9471-13.3333-12.2337-20.0526-10.5047-13.1388100041.101
Inactive10-4.89190.90.709-13.2479-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.6909-2.1257-2.7415-1.45671.4230.53370.4156-2.3538-1.045-5.073-2.362-8.7847-11.0399-3.6909100041.1903
Inactive10-4.64144.95490.57843.5-1.853540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.62650.4697-2.8233-2.4-4.4612-1.6658-0.927-1.6545-0.2803-2.145-0.0407-1.23645.26151.6265100041.1602
Inactive10-4.56044.95490.54737-1.629440 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1793-2.1537-0.4036-2.87041-5.5245-0.3415-3.2205-1.4272-0.2922-5.2662-2.17246.53540.1793100040.9083
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: H2AX721
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 3 uL/well CellTiter-Glo luminescent cell viability reagent (Promega Corporation, Madison, WI) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After incubation at room temperature for 30 min, the luminescence intensity was read using a ViewLux plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000100212 uM-Replicate_1Activity at 0.0000229890 uM-Replicate_1Activity at 0.0000909942 uM-Replicate_1Activity at 0.0002163761 uM-Replicate_1Activity at 0.0005012188 uM-Replicate_1Activity at 0.00103 uM-Replicate_1Activity at 0.00284 uM-Replicate_1Activity at 0.00871 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.051 uM-Replicate_1Activity at 0.114 uM-Replicate_1Activity at 0.255 uM-Replicate_1Activity at 0.582 uM-Replicate_1Activity at 1.781 uM-Replicate_1Activity at 5.430 uM-Replicate_1Activity at 14.00 uM-Replicate_1Activity at 31.63 uM-Replicate_1Activity at 70.87 uM-Replicate_1Activity at 154.2 uM-Replicate_1Activity at 401.1 uM-Replicate_1Activity at 1455.9 uM-Replicate_1Activity at 3087.0 uM-Replicate_1Activity at 6902.0 uM-Replicate_1Activity at 15430.0 uM-Replicate_1Activity at 34510.0 uM-Replicate_1Activity at 77170.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic0.195816.579320Single point of activity-6.70814.95490.6356-17.0793-0.5-30 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.0378-0.07892.0497-4.0824-1.52491.28180.3598-15.06615.2629-1.5796-2.6816-2.6592-1.481-0.0378QC'd by ACCInactive0-7.95813.990.358
Inactive043.2303-5.2610.91491.7511-0.9651.5180.41441.2813-4.8181-8.566-3.01530.40231.03723.2303QC'd by ACCInactive0
Inactive042.6334-0.4566-0.24132.79170.73373.49855.35830.74840.4867-0.23133.50311.23690.75822.6334QC'd by ACCInactive0
Inactive045.14512.97753.87223.1624-2.6383-1.7577-2.117110.59053.2733-0.5395-0.05624.28030.11225.1451QC'd by ACCInactive0
Inactive04-3.6748-2.4298-0.6747-3.1974-7.4289-2.8005-2.60937.3711-4.7494-6.4707-2.9423-3.1292-6.3414-3.6748QC'd by RTIInactive0
Inactive0-4.106310.6242-13.9734-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.97781.6144-1.4479-3.95650.076-5.6314-1.40311.244-2.3399-2.0506-1.5683-5.5983-6.2459-9.9778QC'd by RTIInactive0
Inactive0-4.21014.0950.3917-6.2749-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.0624-0.57771.191-3.8357-1.4631-1.6187-3.87122.41012.2699-1.78380.574-1.198-4.7749-6.0624QC'd by RTIInactive0
Inactive04-6.2845-6.4479-2.6819-0.9491-5.5321-3.63081.9302-1.1485-4.5456-3.1284-3.4839-2.2626-3.9496-6.2845QC'd by RTIInactive0
Inactive0-3.450.90.4298-13.7287-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.7739-0.5915-0.5427-2.26743.129-4.3159-3.0773-0.4174-0.3897-1.8236-7.365-0.639-3.1035-9.7739QC'd by RTIInactive0
Cytotoxic45.904415.988820Complete curve; partial efficacy-4.33814.95490.8599-16.9888-1-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3573-1.6405-0.1185-4.391-3.34390.26140.1829-2.90071.2236-2.46020.516-3.2239-17.4906-15.3573QC'd by RTICytotoxic57.790219.151620Complete curve; partial efficacy-4.23814.95490.6765
Inactive0-4.41173.990.8619-10.9831-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9372-2.0267-0.9393-1.66530.09420.2489-2.1983-0.5132-2.20040.1676-1.8927-6.1292-13.3192-8.9372QC'd by RTIInactive0
Cytotoxic94.101494.77642Partial curve; high efficacy-4.02643.1320.9876-95.3228-0.5468-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.79-2.37250.2589-3.28970.7307-1.0945-0.847-1.70852.7324-3.2271-0.0239-0.2899-30.464-79.79QC'd by RTICytotoxic105.583587.355742Partial curve; high efficacy-3.97644.44950.9851
Cytotoxic127.898275.716942Partial curve; high efficacy-3.89311.210.7142-78.6996-2.9828-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.6209-1.1995-2.582-0.801-0.7702-5.2133-6.0E-4-3.9281-0.099-7.38-6.3771-34.7211-7.476-59.6209QC'd by RTICytotoxic28.6328123.74920Single point of activity-4.54312.40640.8306
Inactive0-3.97460.60.6973-12.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.78030.9175-2.09581.2549-1.23831.43091.0801-2.1662-2.6553-2.8983-4.02-2.9099-5.1369-8.7803QC'd by RTICytotoxic118.957316.037320Partial curve; partial efficacy; poor fit-3.92460.90.7158
Cytotoxic91.940426.641821Partial curve; partial efficacy-4.03653.06540.9323-27.1418-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.86820.53250.7878-0.5764-0.2246-2.89571.3672-1.4009-2.8906-2.8280.19151.1536-10.4047-23.8682QC'd by RTICytotoxic73.030925.702821Partial curve; partial efficacy-4.13653.51170.9553
Cytotoxic90.445521.118220Partial curve; partial efficacy; poor fit-4.04361.88510.6485-24.6182-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.1818-3.5991-0.9613-8.8603-5.261-1.9156-2.4825-12.1501-2.5401-0.8207-5.1003-2.8595-12.2432-22.1818QC'd by RTICytotoxic80.609621.332220Partial curve; partial efficacy-4.09361.88510.8349
Inactive04-7.93740.9285-2.2382-1.0931-2.5705-6.96450.1194-2.3351-0.81211.284-0.7640.8797-5.3686-7.9374QC'd by RTIInactive0
Inactive04-4.5331-1.6685-2.39040.58240.2176-2.6217-3.9140.73360.0474-3.1743-0.0069-2.8617-8.6171-4.5331QC'd by RTIInactive0-5.47880.30.7769
Inactive04-2.3056-1.4405-2.2094-1.8577-1.6091-0.00590.1594-1.4245-0.9456-2.1159-0.5644-1.3464-4.2856-2.3056QC'd by RTIInactive0
Inactive0-4.29720.70.5972-7.6054-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4403-1.6095-0.4996-0.9438-1.2942-0.94991.0478-1.6707-1.3686-1.0617-4.9494-1.064-5.5045-5.4403QC'd by RTIInactive0-3.89720.40.4901
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: HIF512
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using an FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.60324.0950.64957-2.700740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1758-4.2575-0.8849-0.5073-1.8009-7.6673-2.86610.1917-0.6812-1.2122-5.0182-1.00364.92727.1758QC'd by TCIInactive0-7.15323.990.4691
Inactive0-6.75750.20.6588-24.3563-0.170840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.4636-4.8496-8.5344-10.1028-14.3441-10.343-14.2235-11.4306-14.1952-18.1832-11.9322-14.9262-14.9623-24.4636QC'd by SIGMAInactive0-7.55751.62660.7962
Inactive00040.5977-0.7538-0.8916-2.8779-3.0565-5.0177-5.8497-6.2902-0.3941-5.3169-0.7029-2.38370.72570.5977QC'd by ChemServiceCytotoxic17.561183.395741Partial curve; high efficacy-4.75541.62590.9741
Inactive0-4.45440.60.6816-30.3523-2.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.3769-4.6229-0.5495-1.2895-1.1193-12.13114.0955-0.9288-5.7619-9.7965-12.511-12.2886-12.1517-22.3769QC'd by CrescentInactive0
Inactive0-4.95441.88510.9636-30.318-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.03140.50570.3708-1.2987-0.0781-5.2462-1.11230.80840.2592-2.641-8.1573-19.3031-30.265-26.0314QC'd by SIGMACytotoxic22.159172.288720Single point of activity-4.65444.95490.9483
Inactive0-4.20384.50450.676616-2.965540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.8414-4.0057-0.109-1.78660.0869-3.6625-9.5546-4.9082-0.61-2.786-4.3728-2.7969-1.836410.8414QC'd by SigmaAldrichInactive0
Inactive0-4.94951.82650.9274-33.9853-61.540140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.7609-60.7983-57.7742-60.0884-64.8103-59.1302-65.3149-63.658-60.1957-60.6665-54.3555-43.9534-33.3211-38.7609QC'd by SigmaAldrichInactive0
Inactive0004-4.1397-2.9877-1.83381.1979-10.7008-1.7544-1.1569-2.2875-3.3128-2.3864-5.2743-0.26821.7528-4.1397QC'd by SigmaAldrichInactive0-4.70584.95490.7058
Inactive0004-5.8179-5.051-0.68060.5857-0.6234-4.5622-3.8615-1.3297-3.5351-8.9704-10.877-7.88430.1856-5.8179QC'd by SigmaAldrichInactive0-4.3742.33320.6555
Inactive0004-9.9825-1.6216-0.6635-5.2568-0.7064-0.73850.4011-0.9831-5.9428-1.712-6.379-8.825-0.6433-9.9825QC'd by SigmaAldrichInactive0
Inactive0004-8.24010.7083-12.582-1.555-1.5841-0.99266.0648-10.9222-9.8317-1.6314-19.7387-9.04398.5004-8.2401QC'd by SIGMAInactive0
Inactive0-4.91454.95490.540912.51.574440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.3217-0.14334.82590.34674.15480.21845.10389.20720.90632.8403-5.354612.657214.18879.3217QC'd by SensientCytotoxic10.850938.753621Partial curve; partial efficacy-4.96451.88510.985
Cytotoxic38.168351.019720Partial curve; partial efficacy-4.41832.40640.7543-52.141-1.1213-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.531-0.30450.3523-3.7746-0.08513.3224-0.4139-0.226-9.87290.41153.59950.7027-26.9055-42.531QC'd by SIGMAInactive0-4.26834.95490.9124
Inactive00046.73872.7960.1416.00960.266.04240.29035.3783-10.3279-1.3301-1.98070.55341.0526.7387QC'd by SIGMAInactive0-6.55683.06540.7495
Inactive0-4.41582.72020.499213.5-0.204840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.4311-0.1318-0.1192-2.1669-2.4026-0.47710.5652-2.26862.29990.1723-0.219-0.32865.908511.4311QC'd by SIGMAInactive0-5.06583.92950.3811
Inactive0004-1.37410.25470.5081.221-1.343-2.0309-0.68440.0949-1.60341.0326-4.1250.2241-1.2696-1.3741QC'd by SIGMAInactive0
Inactive0-4.39741.10.4549-0.393740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3303-2.31921.414-4.9114-0.3542.6407-0.15680.74260.3671-0.05451.08881.48262.55997.3303QC'd by SIGMAInactive0
Inactive00044.0189-2.49471.2236-0.56551.1538-2.0889-2.06983.13650.5040.18410.37760.58323.45024.0189QC'd by SIGMAInactive0
Inactive00044.07422.03523.4602-0.6876-0.18963.1220.24180.43210.3714-0.80881.43034.6376-1.94074.0742QC'd by FLUKAInactive0-6.37634.95490.551
Inactive0-5.44954.95490.41323.5-1.067440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8554-0.2996-0.2381-3.8228-0.2096-3.80041.63590.3602-2.58850.23935.5561.53523.7894-2.8554QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: H2AX604
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 1 uL/well Supplemented Lysis buffer (diluted 100 fold blocking reagent in lysis buffer) (HTRF Phospho-H2A.X (S139) Assay kit from Cisbio US Inc., Bedford, MA) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After 10sec spin at 1000 rpm in a plate centrifuge, the assay plates were incubated at room temperature for 30 min. Then followed by the addition of 1 uL/well detection buffer (containing a mixture of two antibodies, one labeled with cryptate, Anti pH2AX (S139)-K and another labeled with d2, Anti H2AX-d2) using FRD. After incubation at room temperature for 24 hr, the time resolved fluorescence at excitation 320 nm and emissions at 665 nm and 620 nm was measured using an Envision plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W620-Activity_Score-Replicate_1W620-Curve_Description-Replicate_1W620-Fit_LogAC50-Replicate_1W620-Fit_HillSlope-Replicate_1W620-Fit_R2-Replicate_1W620-Fit_InfiniteActivity-Replicate_1W620-Fit_ZeroActivity-Replicate_1W620-Fit_CurveClass-Replicate_1W620-Excluded_Points-Replicate_1W620-Max_Response-Replicate_1W620-Activity at 0.0000100212 uM-Replicate_1W620-Activity at 0.0000229890 uM-Replicate_1W620-Activity at 0.0000909942 uM-Replicate_1W620-Activity at 0.0002163770 uM-Replicate_1W620-Activity at 0.0005012188 uM-Replicate_1W620-Activity at 0.00103 uM-Replicate_1W620-Activity at 0.00284 uM-Replicate_1W620-Activity at 0.00871 uM-Replicate_1W620-Activity at 0.022 uM-Replicate_1W620-Activity at 0.051 uM-Replicate_1W620-Activity at 0.114 uM-Replicate_1W620-Activity at 0.255 uM-Replicate_1W620-Activity at 0.582 uM-Replicate_1W620-Activity at 1.781 uM-Replicate_1W620-Activity at 5.453 uM-Replicate_1W620-Activity at 14.00 uM-Replicate_1W620-Activity at 31.63 uM-Replicate_1W620-Activity at 70.87 uM-Replicate_1W620-Activity at 154.2 uM-Replicate_1W620-Activity at 401.1 uM-Replicate_1W620-Activity at 1455.9 uM-Replicate_1W620-Activity at 3087.0 uM-Replicate_1W620-Activity at 6902.0 uM-Replicate_1W620-Activity at 15430.0 uM-Replicate_1W620-Activity at 34510.0 uM-Replicate_1W620-Activity at 77170.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-6.95810.40.4668-1.3477-7.973440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4019-5.4309-8.3112-7.4244-5.4208-0.6969-6.5272-2.9697-6.5206-4.8941-0.5496-0.9734-3.7779-2.4019104-0.1994
Inactive104-0.8865-1.2427-0.10122.7689-1.2051-8.0331-5.6601-3.2832-1.2739-1.30180.9228-3.4270.4966-0.8865104-1.2268
Fluorescent55.196533.330110Single point of activity-4.25811.92820.698632-1.330130 0 0 0 0 0 0 0 0 0 0 0 0 0 023.3727-5.2171-8.1918-2.84561.0030.09960-2.16164.727-5.48962.26846.26634.656323.372710-8.20812.24810.3141-1.0212240 0 0 0 0 0 0 0 0 0 0 0 0 0 00.5571
Inactive104-3.0709-9.96180.7982-5.2192-0.5692-7.4363-1.8669-1.2646-6.986367.4176-2.9179-3.7281-0.9825-3.07091042.655
Inactive10-7.72294.95490.339-1.7182240 0 0 0 0 0 0 0 0 0 0 0 0 0 02.61022.22290.57310.318-2.5399-0.2987-1.5265-3.9318-3.3363-3.134-1.9675-1.7341.76152.6102104-0.1089
Inactive1042.7579-1.57941.15321.1346-2.0421.2942-1.69611.24990.9043-2.1472-3.28342.9771-3.35412.7579104-2.7282
Inactive1040.3103-6.58781.75191.80410.9792-3.4345-4.0663-4.2039-4.2626-3.1864-0.08561.4332-0.7270.31031043.6137
Inactive104-1.1081-6.8305-4.7329-5.9552-0.0549-6.737-0.7996-9.2941-6.0746-0.5427-2.1729-2.8132-2.3094-1.10811040.5597
Inactive10-8.350.90.4324-1-10.594340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4474-5.3962-0.0826-3.1558-1.3558-0.4378-3.4408-2.8376-1.0188-0.97340.8621-1.9522-1.96323.4474104-4.44
Inactive104-0.7343-8.0348-3.0411-0.1542-1.28041.7882-1.1388-9.1341-4.2303-2.967-1.0623-1.1713-0.1655-0.734310-3.78814.95490.5013-5.32120.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.7677
Inactive10-6.71171.62660.3188-0.5-2.820840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.2805-0.0514-4.2641-2.6332-4.8507-0.5406-1.432-1.41880.7593-1.54291.0907-1.0329-2.0198-1.28051040.481
Inactive104-11.2334-7.1625-2.2867-5.4475-3.7778-2.3395-7.3034-0.3656-3.4483-9.3653-5.5476-10.4351-11.3637-11.23341044.3704
Inactive104-2.86241.0493-2.5635-1.9363-0.226-2.2897-2.38710.5577-1.1759-2.1626-3.16020.4219-0.9845-2.86241042.242
Inactive104-1.6903-1.0786-2.1965-1.3298-0.06540.0541-3.2054-1.5765-5.5016-5.03210.1563-0.4334-3.7092-1.69031040.1926
Inactive1041.1876-1.5971-4.1158-1.27110.0502-3.6804-4.3519-3.952-1.267-0.0663-0.569-7.508-2.8771.18761041.4021
Inactive1040.24620.6799-1.6187-2.99681.55590.7002-0.4152-0.23540.933-1.4204-2.95051.2689-2.16810.2462104-1.6194
Inactive104-2.21620.1318-2.90266.8735-2.20941.0407-1.7947-2.3121-4.59980.82981.171-5.44561.1958-2.2162104-2.9548
Inactive1040.65650.6163-1.1595-0.8031-2.2181.3415-4.049-3.3028-3.4787-2.39650.1898-0.73210.38440.6565104-1.8324
Inactive1041.1241-8.5235-3.20041.8669-4.8174-0.1069-0.6147-2.4142-1.0633-2.48770.1282-1.2367-1.58931.12411040.1357
Inactive10-6.94720.80.4048-0.5-3.161940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1519-2.2985-3.492-1.744-3.1132-2.3395-0.2181-1.8917-0.8137-1.06751.9967-2.542-1.2665-3.15191040.9974
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV463
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive041.72950.52943.18025.8576-13.2261-2.70962.32773.08360.66810.8553-2.5716-8.80020.93361.7295QC'd by ACC0
Inactive0-5.67134.95490.4567-9.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.4931-0.3132-9.0031-1.37862.9342-0.62741.4692.0742-1.31910.8343-7.1697-14.1560.3555-9.4931QC'd by ACC0
Activator16.9301626.649349Partial curve; high efficacy-4.77131.3310.9768639.241312.5922.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0495.5359-1.9437-0.28722.264960.37582.736523.80731.9884.584813.458684.9728135.6152319.9522495.5359QC'd by ACC0
Inactive0-9.17134.95490.3243-4.16692440 0 0 0 0 0 0 0 0 0 0 0 0 0 14.49519.1079-2.92392.9475-1.1252-3.1158-19.7224-18.7137-5.55731.73914.3407-0.5794-17.21864.495QC'd by ACC0
Inactive04-1.4338-5.1613-13.4065-11.08192.2196-9.8309-7.493519.6175-11.68-6.5454-3.0084-1.3924-0.0854-1.4338QC'd by RTI0
Inactive04-0.06572.7267-14.8963-0.59042.5835-4.97911.54130.4423-5.1268-14.4299-8.05080.6303-10.6572-0.0657QC'd by RTI0
Inactive04-2.2898-1.05085.84332.72411.9566-1.76592.149-5.0045-8.03727.387518.2729-3.414514.9169-2.2898QC'd by RTI0
Inactive04-2.66921.559137.22210.9092.2412.8103-4.2918-5.3244-6.3058-0.6797-2.999917.4880.0577-2.6692QC'd by RTI0
Inactive04-7.8369-7.29973.8528-6.08521.198756.327-0.252-6.6076-2.0431-2.85932.836660.13680.7004-7.8369QC'd by RTI0
Inactive0-7.90134.44950.42791-11.008940 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1506-12.4702-10.9207-3.67122.24471.34810.8136-4.3714.0377-2.89721.43973.8914-3.2241.1506QC'd by RTI0
Inactive041.11810.1768-5.3052-0.94990.09024.06750.0846-0.6164-0.42438.7148-3.13170.6008-2.02271.1181QC'd by RTI0
Inactive0-7.78970.80.3897-2-17.425340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.4437-14.023-15.1485-15.88081.8136-13.5013-8.13622.80881.5308-16.02122.2517-5.7850.4858-11.4437QC'd by RTI0
Inactive04-10.42311.28533.5569-3.1220.92258.3539-5.9784-6.6058-9.2911-3.1787-3.4870.71291.4318-10.4231QC'd by RTI0
Inactive0-7.73824.95490.30320.011512.211240 0 0 0 0 0 0 0 0 0 0 0 0 0 11.52880.950616.703814.1576-2.5052-1.4079-7.1617-2.59110.2899-1.46337.03017.09990.33931.5288QC'd by RTI0
Inactive0-8.54990.80.6938-2.94661840 0 1 0 0 0 0 0 0 0 0 0 0 0 0-4.125112.009133.24450.68950.67250.2088-2.7945-1.4329-3.4616-5.9923-1.3187-2.4253-0.3401-4.1251QC'd by RTI0
Inactive04-0.8939-2.9136-1.9824-0.2399-1.3445-0.37655.8516-2.01614.2702-3.190856.3924-0.94610.5242-0.8939QC'd by RTI0
Inactive04-8.7412-6.5753-17.70663.7172-10.82516.8532-5.6494-1.0518-7.7844-4.0289-6.4104-4.9608-14.2816-8.7412QC'd by RTI0
Inactive04-8.43490.6625-12.86764.0735-4.892734.2082-7.0634-7.0056-4.6588-0.7159-10.6746-6.22913.8264-8.4349QC'd by RTI0
Inactive04-8.0905-8.9909-7.30310.6324-11.7986-17.7946-11.0081-10.6951-13.728-15.7973-13.7019-0.8883-7.3389-8.0905QC'd by RTI0
Inactive047.7339-3.1519-12.65715.9451-3.8215-9.616611.4708-10.59340.5021-4.2503-7.881-10.49670.61947.7339QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV208
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive042.8556-6.3304-0.7647-8.8733-1.31120.8858-0.7954-2.57631.03362.1512-9.58190.21270.5852.8556QC'd by SIGMA0
Inactive04-7.8426-4.3078-16.60170.242-13.2719-11.6752-0.79161.95570.8861-16.7872-2.3074-10.3741-2.8885-7.8426QC'd by SIGMA0
Inactive0-4.21014.95490.4665320.65440 0 0 0 0 0 0 0 0 0 0 0 0 0 025.3647-1.024-9.455-4.84037.0107-0.83190.7153-0.51971.3173-2.122121.3-1.94980.638125.3647QC'd by SIGMA0
Activator10.9622354.094588Complete curve; high efficacy-4.96011.88510.9871350.4672-3.62731.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0308.1942-1.3985-5.089-0.241-8.8635-0.459-5.64280.57321.391323.285681.7578248.9758341.586308.1942QC'd by SIGMA0
Inactive0-4.21034.95490.404514-0.05940 0 0 0 0 0 0 0 0 0 0 0 0 0 011.96942.92772.7682-4.33181.2545-0.3862.9265-3.3749-0.10960.69872.85880.883-6.299211.9694QC'd by SIGMA0
Inactive04-13.0353-2.27130.1463-3.5651-12.8612-3.9456-7.20940.7903-1.74652.1902-4.8911-11.17319.074-13.0353QC'd by Enamine0
Inactive0-4.66014.95490.572422-4.384840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1612.5163-10.0126-10.1585-10.3418-5.59460.93372.7621-4.0144-12.8206-6.8537-0.243720.2317-3.161QC'd by Acros0
Inactive04-7.4276-3.9949-3.4557-6.7725-8.6378-3.7241-4.4626-9.5948-6.0438-0.4032-7.51030.5018-6.0984-7.4276QC'd by SIGMA0
Activator54.941165.51310Single point of activity-4.26014.95490.9754156.7033-8.809730 0 0 0 0 0 1 0 0 0 0 1 0 0 0131.9051-3.0176-7.8198-5.984-12.7666-12.3564212.7294-11.8023-3.2899-12.078168.6093-7.3461-9.2414131.9051QC'd by LightBiologicals0
Activator21.8724188.631741Partial curve; high efficacy-4.66012.63840.9884181.566-7.06562.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0189.1313-6.8974-9.5309-15.2558-4.7097-9.1661-13.1889-0.3751-4.4697-4.7565-3.896451.8043130.9924189.1313QC'd by SIGMA0
Inactive0-4.46011.210.5164-15.5464-141 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.955414.77360.1105-0.3273-0.6686-1.19261.6937-0.1163-2.6784-9.52550.8128-1.5346-10.5306-12.9554QC'd by SIGMA0
Inactive0-4.21014.95490.465-22.3147-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.92891.2242-10.46842.60172.96771.2054-1.31262.3634-4.18770.0322-1.4713-0.911-0.8096-16.9289QC'd by Enamine0
Inactive044.45532.40422.23260.41450.24591.92160.4022-0.87521.5279-1.3064-0.98321.2208-0.59624.4553QC'd by LightBiologicals0
Inactive040.31653.88260.36471.64325.15721.7629-7.38692.44130.0071-1.3988-7.01262.4097-0.29750.3165QC'd by SIGMA0
Inactive04-1.8527-6.04173.3136-21.7204-0.80272.34064.71844.32133.25283.59745.3302-0.15211.3023-1.8527QC'd by SIGMA0
Activator3.8895232.94451Partial curve; high efficacy-5.41011.47870.9923230.9277-2.01642.10 0 0 0 0 0 0 0 0 0 0 0 0 1 162.38620.4013-5.072-0.61550.58821.3374-1.29933.258221.944396.8738157.7951204.7231124.904862.3862QC'd by SIGMA0
Inactive04-3.47891.4151-13.25430.1998-1.77564.16140.810614.65013.76140.68722.5933-0.70390.494-3.4789QC'd by ChemService0
Inactive0-5.36014.95490.3211-5.731040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.73460.55414.9704-5.8731-0.6018-6.8821-1.45694.11891.88980.1337-7.25430.1379-8.5259-6.7346QC'd by SIGMA0
Inactive040.0083-0.6469-9.92481.92781.2911-0.062-5.6651-3.0476-0.16126.3388-7.89081.4553-6.56660.0083QC'd by SIGMA0
Inactive0-7.61014.95490.3777-1.7299640 0 0 0 0 0 0 0 1 0 0 0 0 0 01.83795.69061.496510.08612.0512-2.1055-0.94551.516621.5335-14.3582-0.32220.0976-0.37391.8379QC'd by ChemService0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV378
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-4.9327-8.7446-7.1163-2.5925-13.0435-1.7843-2.484-3.6729-7.613-0.8889-4.8878-7.5645-0.6005-4.9327QC'd by SIGMA0
Inactive04-16.415-8.5001-2.0629-19.3599-6.5839-1.4707-9.8236-3.5022-4.2079-3.24190.1219-5.8248-9.6459-16.415QC'd by SIGMA0
Inactive04-10.7413-7.39220-0.2838-0.5653-4.5221-3.0423-6.7941-2.6028-14.553-0.3935-3.6205-12.0068-10.7413QC'd by SIGMA0
Inactive043.2663.16150.08866.5708-1.32983.14050.67442.5665-6.09993.2181.004916.1034.23573.266QC'd by SIGMA0
Cytotoxic54.799939.068320Single point of activity-4.26124.95490.6959-38.67160.3967-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.39179.59144.3283-0.759-4.06415.535-4.0123-9.3196-1.0468-1.3955-5.42130.0991-1.6536-32.3917QC'd by SIGMA0
Inactive04-5.73092.4973-8.6586-4.0186-3.069512.231313.719.8546-5.47310.4059-3.83138.4712.9818-5.7309QC'd by SIGMA0
Inactive0-7.05671.96730.5185-1.2735.540 0 0 0 0 0 0 0 0 0 0 0 0 0 110.3592.8275.80910.02684.8573.60620.9278-1.1672-0.7265-0.7966-6.4775-0.77652.138810.359QC'd by SIGMA0
Inactive0-8.01492.33320.3168-1.860140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.70960.2868-5.71687.12927.41961.630516.89211.03154.11626.683716.156210.6194.529213.7096QC'd by SIGMA0
Inactive0418.46045.7588.027-2.207411.8158-1.23930.152411.417911.842511.9427.8774-0.79384.7718.4604QC'd by SIGMA0
Inactive04-3.1832-3.0169-21.80232.0915-0.17060.85444.67233.83911.6775-3.1957-4.5826-1.7625.6197-3.1832QC'd by SIGMA0
Inactive047.06459.82295.06560.6911-2.4601-2.9394-0.43582.99575.00434.57664.344910.4285.47957.0645QC'd by SIGMA0
Inactive042.87990.629-10.63982.0031-0.51151.142-1.08143.68224.59776.9657-0.74484.399614.49732.8799QC'd by SIGMA0
Inactive041.50152.66799.95341.34317.349517.04560.9676-3.3756-0.89150.99653.49348.230615.41721.5015QC'd by SIGMA0
Inactive04-4.07418.0515-9.6192-9.13193.341-15.15631.344611.16750.4706-5.54756.1638-8.9391.0036-4.0741QC'd by SIGMA0
Inactive0419.28391.7535-1.83222.628214.76662.45912.84031.7826-3.637912.539-0.274713.7515-2.088619.2839QC'd by SIGMA0
Inactive04-6.837-4.13767.35992.9047-1.07680.16948.3141.13760.9196-7.8482-6.9238-0.58641.4242-6.837QC'd by SIGMA0
Inactive0-5.70660.70.566221.939140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1135-1.102106.448313.25958.79225.6758-3.3848.396913.63420.653922.032513.87680.1135QC'd by SIGMA0
Inactive049.5114.849813.2582.0698-2.30842.241823.650616.2267-0.179922.16161.8408-0.3677-0.42029.511QC'd by SIGMA0
Inactive0-4.24844.95490.446625-0.037740 0 0 0 0 0 0 0 0 0 0 0 0 0 020.76270.901-2.66373.17736.35525.97582.4992-2.72392.61-0.87970.7471-17.94812.574120.7627QC'd by SIGMA0
Inactive04-10.2166-8.0741-1.4322-10.2813-2.02430.8873-4.2479-4.2814-3.429-4.25980.2946-0.0902-2.3971-10.2166QC'd by TCI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV365
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator8.485286.606643Partial curve; high efficacy-5.07132.40640.976389.16782.56122.10 0 0 0 0 0 0 0 0 0 0 0 0 1 086.90821.02660.05454.52680.01668.86952.65560.78571.9848-1.729210.014540.5982151.254986.9082QC'd by Vitas0
Inactive0-5.57134.95490.677913.5-8.357740 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6815-0.32180-6.2613-9.9352-14.3533-14.1175-8.9264-13.9610.3022-4.10819.06623.313517.6815QC'd by GVK0
Inactive042.646-6.42590-4.1621.831-8.0314-4.78624.5388-12.654-4.28110.969-4.2381-0.15752.646QC'd by GVK0
Inactive0-8.72132.72020.4352-2-14.028340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-14.1844-14.6069-10.5571-3.5931-0.24434.3078-13.0836-0.4989-10.2984-1.20991.2966-1.1947-0.2081-14.1844QC'd by SIGMA0
Inactive04-3.475505.507-0.7209-2.3493.63873.73590.8937.34436.5535-1.6209-3.779416.6908-3.4755QC'd by Vitas0
Inactive0-4.67131.44870.475420-1.214840 0 0 0 0 0 0 0 0 0 0 0 0 0 014.54470-12.2623-0.7698-7.24351.02327.2280.10374.4052-0.963-0.62993.19686.097214.5447QC'd by GVK0
Activator26.832592.231910Single point of activity-4.57134.95490.894483.3113-8.920630 0 0 0 0 0 0 0 0 0 0 0 0 0 075.0566-10.44290-9.88480.1396-10.1825-9.9995-17.11032.4671-2.7879-10.8915-23.1147-5.328475.0566QC'd by GVK0
Inactive0-8.17134.95490.3427-3.1739340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.58472.37223.77442.3601-8.612-3.4854-2.7786-8.8949-7.2433-2.8949-2.4933-0.32235.0376-0.5847QC'd by Bosche0
Inactive0-5.67134.95490.4487-12.8572140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.593504.65213.2642-5.54511.15910.7332-1.1835-1.49942.4658-8.72362.9154-21.5477-0.5935QC'd by GVK0
Inactive048.81960-0.4241-1.8954-7.95630.5962-8.24726.0735-0.25930.7421-0.1487-2.9588-0.70858.8196QC'd by GVK0
Inactive04-0.0567-1.1379-12.553-7.81915.4588-10.82372.7893.17920.9157-0.642-9.1488-4.9765-9.6703-0.0567QC'd by GVK0
Inhibitor16.930146.90560Single point of activity-4.77131.10.5088-48.2775-1.3719-30 0 0 0 0 0 0 0 0 0 0 0 0 0 1-23.03270-0.6207-0.43857.14511.3083-0.19720.1005-14.869-12.0261-6.8573-0.2305-36.5738-23.0327QC'd by GVK0
Inactive04-19.84640-2.6054-13.7849-2.4577-5.7211-16.7659-10.3853-0.7293-3.0864-6.492-5.1247-16.5498-19.8464QC'd by Microsource0
Inactive04-16.345400.27621.67361.0416-0.26852.6855-19.9410.7119-13.46282.0044-4.5615-2.2088-16.3454QC'd by GVK0
Inactive0-5.42131.37230.39735-8.83940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-10.4536-19.86580-10.924-9.1864-6.1797-0.4783-11.1336-11.2034-11.5766-2.38671.11013.7454-10.4536QC'd by GVK0
Inactive04-9.39580-15.25711.24530.13414.95650.82550.2492.19480.29451.70286.08761.8921-9.3958QC'd by GVK0
Inactive0-4.97133.990.6676-22.85242.540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.38073.96586.37570.71051.94388.3116-5.8821-7.17957.95175.79273.7389-1.6269-24.04370.3807QC'd by GVK0
Inactive04-15.7547-16.86130-0.9266-9.3733-1.5706-13.3964-10.692-0.2257-0.0563-16.54230.9534-15.7303-15.7547QC'd by Tocris0
Inactive04-1.84144.3389-3.50071.7649-15.66832.00261.42850.8835-5.8273.40023.368148.89163.8973-1.8414QC'd by GVK0
Inactive043.5266-8.2360-1.899813.78435.228413.5915-3.3487-0.21965.29895.1035-0.14670.7463.5266QC'd by GVK0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV822
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic8.485243.048321Partial curve; partial efficacy-5.07132.35310.8574-38.89694.1515-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.78545.2831-0.16240.02640.99280.74150.9842-2.518910.176216.18536.2409-17.4861-26.8257-40.7854QC'd by Microsource0
Inactive0-7.62133.06540.48067.5-2.760240 0 0 0 0 0 0 0 0 0 0 0 0 0 09.8114-0.9727-4.8469-2.6345-0.84613.14139.363-2.604112.50013.610410.192913.01110.00269.8114QC'd by Selleck0
Cytotoxic9.520586.722142Partial curve; high efficacy-5.02131.75290.9689-85.47251.2496-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-89.03383.36492.4659-0.68964.1315-0.81468.47012.1755-7.08250.0244-7.2368-31.3673-56.5649-89.0338QC'd by Microsource0
Inactive041.93340.41322.1328-1.066.91535.40546.77751.1052-4.4176-32.2423.65730.28429.20631.9334QC'd by SIGMA0
Cytotoxic16.930149.723321Partial curve; partial efficacy-4.77132.40640.8642-49.8188-0.0955-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-43.80211.124-0.4846-0.12142.51935.40014.2115-0.145-1.7743-12.87050.9978-6.6548-25.0298-43.8021QC'd by Microsource0
Inactive040.683-6.0203-3.0276-0.4228-0.6535-0.283-0.7135-0.9467-5.0249-0.5891-7.1629-10.3891-2.11390.683QC'd by Labotest0
Inactive04-7.88634.66455.187-0.83962.96212.4404-5.26055.43432.5966-3.7984-1.85873.35973.0908-7.8863QC'd by SIGMA0
Inactive0-4.52134.95490.5144-19.936-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.6133-4.90210.2671-1.1373-1.15194.0221-2.8879-1.5786-7.5865-4.8278-2.60048.0241-0.7001-16.6133QC'd by Microsource0
Inactive0-6.32134.95490.377-3.5899540 0 0 0 0 0 0 0 0 0 0 0 0 0 110.25151.027710.59696.15660.8041-0.23631.03779.82677.8327-6.84410.3465-10.90820.083110.2515QC'd by Vitas0
Inactive042.26870.07791.88060.76273.75511.5221-1.36212.4817-1.4475-14.386-5.7175-5.3274.762.2687QC'd by Labotest0
Cytotoxic4.252751.912722Complete curve; partial efficacy-5.37131.62660.9453-50.91390.9987-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.60345.0384-4.89210.0860.27024.4697-0.48647.16770.4012-2.2223-14.1412-35.4965-52.845-39.6034QC'd by Specs0
Inactive043.287913.20085.99150.5737-0.10155.9296.2916-7.1749-0.74236.17374.413717.98546.41423.2879QC'd by Specs0
Inactive0413.007-4.9949-0.0285.0288-0.542-4.44245.59557.37523.9094-14.83655.1595-1.9929-0.39713.007QC'd by Labotest0
Inactive040.12657.25313.79420.7983.45041.67535.36611.05630.3063-17.30017.0679-3.8381.71970.1265QC'd by Labotest0
Inactive042.7567-1.3486-0.00990.73422.55193.1976-2.524-0.3468-9.6554-2.0931.0802-7.75972.95282.7567QC'd by SIGMA0
Inactive040.82523.12132.30920.0513.4197-0.9374-2.4367-1.9651-1.86492.46166.8884-3.55262.03030.8252QC'd by Specs0
Inactive0412.82342.4425-0.44610.43694.86624.188510.4156-0.0871-0.697-3.82816.2664.859211.104912.8234QC'd by Microsource0
Inactive04-0.593910.4617-0.31641.75264.5012-1.244511.50844.7483-7.8273-15.77046.2867-11.03125.8757-0.5939QC'd by SIGMA0
Inactive0-9.22134.95490.3854-0.54251440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.969610.213-0.2751.2734-1.8998-0.71614.12091.13-0.0525-0.18393.4979-7.5354-3.7917-3.9696QC'd by Labotest0
Inactive042.9699-3.79022.1807-1.7828-0.88182.4962-2.6747-1.75432.2139-3.24690.6907-10.07222.27182.9699QC'd by Vitas0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV159
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.86410.80.3875131.048140 0 0 0 0 0 0 0 0 0 0 0 0 0 08.45341.2371-0.31680.2815-0.578510.0845-0.7819-3.70995.6634-0.2285.90985.358212.5448.4534QC'd by SIGMA0
Inactive0-8.90214.95490.47680-14.237440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.3106-3.9679-0.9064-0.1971-0.8477-4.1457-0.99771.62460.0931-1.33841.2572-0.6955-4.80345.3106QC'd by SigmaAldrich0
Inactive041.02930.32712.1540.4664-2.179-1.40230.14798.66543.41155.92726.5917-8.36457.96631.0293QC'd by SigmaAldrich0
Inactive0-5.55890.20.327514-13.037440 0 0 0 0 0 0 0 0 0 0 0 0 0 00.1893-5.3527-18.3645-3.3463-3.6483.8982-10.3569-1.041-2.317-3.35086.8459-3.103313.54620.1893QC'd by SigmaAldrich0
Inactive0-5.6994.95490.41515.5-1.280440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.4673-3.909-1.8456.07946.6348-2.5062-1.5818-3.8038-2.42534.67185.27866.29415.0596-3.4673QC'd by SigmaAldrich0
Inactive040.5688-4.1372-0.3967-1.5611-3.285-1.1585-0.018710.4505-2.9705-0.3053-0.0983-7.1629-1.33140.5688QC'd by SigmaAldrich0
Inactive0-4.2094.95490.3908-17.7069-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.50574.8097-1.6942-1.3834-7.5388-1.7719-1.2029-0.35810.901-1.4353-4.5824-3.66553.1971-13.5057QC'd by SIGMA0
Inactive04-1.27973.5207-2.49483.96232.6849-1.5310.8881-10.4751-1.28212.18786.4139-2.49510.2085-1.2797QC'd by SIGMA0
Inactive041.0283-0.4756-12.3001-5.5103-0.1743-2.6256-11.4404-11.6686.2351-2.2512-5.1080.7848-7.34241.0283QC'd by SIGMA0
Inactive040.94320.75940.988318.962614.29172.15132.42865.69981.2613-2.7951.06240.2146-0.08770.9432QC'd by SIGMA0
Inactive049.853413.81771.538511.23119.684-0.0199-6.0352-4.37145.66948.41082.47796.4969-0.04439.8534QC'd by SIGMA0
Inactive0-4.21124.95490.3412-21.4496140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.2083.68444.35545.11454.10112.6662-13.7864-12.28431.06224.32628.4508-1.3872-0.1594-16.208QC'd by Research Biochemical0
Inactive04-19.3036-0.62070.8664-0.571912.3734-3.2162-22.2356-24.4009-8.45971.4920.108-2.53653.6237-19.3036QC'd by SigmaAldrich0
Inactive044.475-0.0376-1.2614-13.0749-2.47974.008-1.9292-25.97930.848-3.96914.06111.21292.53564.475QC'd by SIGMA0
Inactive0-5.25624.95490.6306-16.9047-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.92063.868-2.4948-1.9864-2.15751.4413-8.4707-9.35272.34873.2139-14.7451-14.2038-10.519-24.9206QC'd by ChromaDex0
Inactive0-5.30964.95490.7023-20.9197040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.63411.55125.2906-0.74095.3658-4.31030.1166-18.17714.309-0.0902-18.3205-24.9331-17.6239-19.6341QC'd by SIGMA0
Inactive041.0091-0.61491.64853.05532.21034.3448-0.1307-22.67423.64670.6253-1.0888-7.05951.12483.23981.0091QC'd by SigmaAldrich0
Inactive0-4.8082.35310.425623.5-2.20840 0 0 0 0 0 0 0 0 0 0 0 0 0 17.46058.2789-2.64731.954-0.8692-2.1201-19.34-16.0592-1.36042.0296-0.129110.618819.86147.4605QC'd by Sensient0
Inactive0-5.06711.47810.789718-3.291540 0 0 0 0 0 0 0 0 0 0 0 0 0 14.8784-2.903-3.31612.663-3.8778-2.2076-9.4096-6.5877-2.42054.94120.956515.029214.83874.8784QC'd by Pfaltz-Bauer0
Inactive040.898-5.144-4.4883-2.145-3.463110.3215-3.9271-11.130.5937-1.5597-0.85449.81064.98280.898QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV202
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-7.3758-0.7877-3.27010.0141.7013-7.8748-5.1827-6.2686-5.1561-9.3082-7.68583.5929-10.2498-7.3758QC'd by SIGMA0
Activator38.895279.901140Partial curve; high efficacy-4.41011.62590.919479.0967-0.80442.10 0 0 0 0 0 0 0 0 0 0 0 0 0 062.62023.40484.07381.00250.2637-12.7877-4.81713.4033-2.5478-3.68727.384317.327728.845262.6202QC'd by Sigma DiscoveryCPR0
Inactive0-4.21014.95490.481218-2.238940 0 0 0 0 0 0 0 0 0 0 0 0 0 013.0644-0.5726-5.79248.04180.172-2.137-4.1871-4.2849-3.8138-3.3394-1.6984-3.5829-1.391613.0644QC'd by MP Biomedicals0
Inactive040.85863.7707-5.1242-1.77548.6578-1.36621.28759.5889-0.6112-3.13740.2344-0.1463-0.03380.8586QC'd by SIGMA0
Inactive0-4.66034.95490.45164-2.444840 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5724-2.3541-3.77710.1128-3.6013-0.1967-4.8326-4.4902-3.261-4.743.4-3.36754.87433.5724QC'd by SIGMA0
Inactive04-1.5792-2.9775-0.3082-0.04085.552-3.0376-2.12742.9081-0.972.5571.60563.5688-2.1154-1.5792QC'd by SIGMA0
Inactive04-3.24114.6629-9.8321-1.2555-0.62083.887637.4278-0.7186-1.7803-2.6711-0.3958-5.13894.204-6.6116-3.2411QC'd by LightBiologicals0
Inactive04-5.77253.35435.5606-2.5150.74692.54313.08292.51132.94125.8043-4.1459-2.9981.1272-5.7725QC'd by SIGMA0
Inactive049.3453-3.0587-4.72780.6755-8.6618-3.6004-5.1899-2.69986.02765.8959-5.73-4.471-6.03629.3453QC'd by LightBiologicals0
Inactive0-5.91010.60.3202-6.93283.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.1107-1.853713.76847.1434-1.18787.8068-5.8411-1.82650.1382-2.5712-4.2462-5.6582-1.5684-9.1107QC'd by LightBiologicals0
Inactive04-7.2151-1.72950.43414.99610.2796-7.5367-0.33556.84274.6981-5.72771.09072.29352.3957-7.2151QC'd by SIGMA0
Inactive0-4.310110.4216-20.0887440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.40725.66480.2326.04583.2443-4.77913.9750.174910.9938-0.8349-1.3601-4.90460.5697-13.4072QC'd by SIGMA0
Inactive040.6747-1.30960.7316-5.2078-1.4784-6.1707-6.31822.1785-3.7947-1.0003-9.8199-1.578-8.40360.6747QC'd by SIGMA0
Inactive04-12.0085-4.09926.0584-9.4685-6.9633-2.2557-10.5533-7.35350.0130.1836-5.8167-9.1387-9.2296-12.0085QC'd by LightBiologicals0
Inactive0-5.41014.95490.39786-0.856140 0 0 0 0 0 0 0 0 0 0 0 0 0 011.49650.531.2909-1.7803-2.687-3.21340.3726-1.76910.7235-1.336912.57980.61090.089411.4965QC'd by SIGMA0
Inactive04-1.4682-5.3624-8.5522.0405-7.7996-0.1045.64176.60932.2753-11.41981.35823.17015.317-1.4682QC'd by SIGMA0
Inactive04-1.9548-0.3469-4.1930.233-2.7259-4.12371.5867-4.0101-1.589-0.0441-3.4171-9.53152.4248-1.9548QC'd by ChemService0
Inactive0-7.76014.95490.4769-5.914-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1452-1.6157-1.51762.4522-6.9585-1.8215-10.345-6.1183-4.7003-5.1159-3.3985-10.2328-7.53292.1452QC'd by SIGMA0
Inactive0-4.3144.95490.551329-1.795440 0 0 0 0 0 0 0 0 0 0 0 0 0 026.0201-3.9988-3.4143-3.1105-5.653-9.4128-0.3653-2.86348.1995-0.4057-2.051-1.87522.884326.0201QC'd by EPA0
Inactive04-9.717-7.55361.8624-10.8397-5.44331.22650.7592-7.2226-7.1647-0.1417-7.8421-2.1024-1.104-9.717QC'd by Crescent0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV689
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic55.66169.607241Partial curve; partial efficacy-4.25443.24750.9645-71.0973-1.4902-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-53.86160.84590.21760.4959-3.3673-7.9542-0.4850.87850.2602-5.05280.0844-4.8395-13.5588-53.8616QC'd by LKT Lab0
Inactive0-4.87270.60.4492-17.2481-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.9129-0.8708-0.9932-0.10140.8045-5.952-6.14190.26580.39880.1889-9.0811-0.5996-14.3735-10.9129QC'd by SIGMA0
Inactive0-5.07054.95490.3261-5.4821040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.688-1.99182.4151-1.2712.27-2.15421.3835-0.02690.05581.7737-1.9944-1.9489-7.4851-3.688QC'd by TCI0
Cytotoxic21.826933.994620Partial curve; partial efficacy-4.6611.75290.8595-35.9946-2-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-35.2888-1.1158-0.2481-0.8283-1.2075-4.79370.1012-5.5396-6.2014-0.1408-0.218-21.4998-19.1186-35.2888QC'd by SIGMA0
Inactive0-5.25394.95490.7479-11.0575-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.3280.3836-1.04820.81271.5291-7.0143-0.1714-0.27880.530.2131-0.4784-10.2064-13.3812-8.328QC'd by SIGMA0
Cytotoxic55.9441106.675320Single point of activity-4.25224.95490.9863-107.4649-0.7896-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-90.0041-0.1260.08581.2517-0.07862.89171.29111.9346-2.42210.041-1.1903-8.6058-9.9229-90.0041QC'd by SIGMA0
Inactive00040.02360.1055-0.2139-0.4297-0.4957-10.1401-1.2193-6.2121-2.65490.1198-1.2053-0.44750.05790.0236QC'd by SIGMA0
Inactive0-5.07244.95490.6859-14.4467-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.80170.13851.62530.6342-0.9523-1.91720.7988-10.21540.48713.33980.9245-6.413-17.8723-10.8017QC'd by SIGMA0
Inactive00042.02441.42183.16263.0023-0.4824-1.93081.39912.14280.549-13.883-0.379-2.92421.7412.0244QC'd by SIGMA0
Inactive0-4.61251.85790.8312-22.61371.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.84471.1503-0.74640.39311.16184.67261.93011.81551.74520.60135.3411-12.0389-8.7286-23.8447QC'd by SIGMA0
Inactive0004-3.4271-0.3776-0.65160.0179-0.282-0.8236-0.26560.06060.1454-0.038-0.2845-2.6228-3.2934-3.4271QC'd by SigmaAldrich0
Inactive0-4.36413.1320.7553-19.8489040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.9574-0.35731.30171.27941.83152.6845-0.9184-2.10761.877-8.15250.66380.7179-6.8277-16.9574QC'd by SigmaAldrich0
Inactive0-4.84980.90.4941-20.5874-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4895-0.06681.3428-2.82980.6418-9.4205-6.8736-9.5814-0.3393-2.6082-0.2259-12.6383-12.3502-15.4895QC'd by ChromaDex0
Inactive00041.29060.47550.41140.1566-5.70441.73831.15671.4254-0.6115-3.4652-1.48130.36221.46221.2906QC'd by SIGMA0
Inactive00041.1901-0.2219-1.1968-3.4803-0.2969-4.40061.31262.89211.22671.1129-2.67862.3447-2.48061.1901QC'd by SIGMA0
Inactive0004-0.32953.38480.49230.807-1.393-1.3621.21123.57983.0263-0.9962-0.91862.34311.8549-0.3295QC'd by SigmaAldrich0
Inactive00043.4046-0.9813-0.2358-0.4965-0.0873-0.1523-2.4317-1.2237-0.7157-2.6104-4.09132.0322-5.73393.4046QC'd by SIGMA0
Inactive0004-1.80820.72851.32342.6709-4.3133-0.8979-0.63640.1574-2.29363.81920.2489-2.08541.7416-1.8082QC'd by SigmaAldrich0
Inactive0-4.70871.28760.8517-17.6909040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.7424-0.1759-0.9468-0.7564-0.056-0.56420.1765-0.33072.2008-6.7251-1.8381-5.6854-13.4326-14.7424QC'd by SigmaAldrich0
Inactive00043.0880.9806-0.0673.7852-0.37390.58322.31010.15290.05232.1308-0.21190.1292-0.50213.088QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV894
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-2.6026-1.7975.89993.0748-15.192-5.1959-4.64860.07135.84590.242-2.4397-10.3851-7.7055-2.6026QC'd by ACC0
Inactive0-5.62134.95490.5983-13.8026-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.03940.7082-7.1062-6.45310.9924-5.73244.95740.5469-0.5803-0.1158-7.0559-15.2522-9.1362-15.0394QC'd by ACC0
Activator18.99591238.497154Partial curve; high efficacy-4.72131.55790.98671257.124618.62752.10 0 0 0 0 0 0 0 0 0 0 0 0 0 01002.4917-0.6422-1.2054-0.772550.264311.645820.54550.93771.224928.1656124.6638254.3234546.90561002.4917QC'd by ACC0
Inactive0-8.47131.88510.4864-2.15241940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.048923.86114.4099.31771.26670.7891-11.6442-12.6270.8718-4.89584.29410.52630.98980.0489QC'd by ACC0
Inactive0-5.63624.95490.3755-0.5-9.203940 0 0 0 0 0 0 1 0 0 0 0 0 0 02.2375-5.0601-12.9044-13.83432.6465-9.2201-8.212832.5557-12.3972-9.49852.865-6.5312-2.82972.2375QC'd by RTI0
Inactive04-1.28022.6074-15.4650.13821.22230.25050.94971.3356-4.3854-11.9115-1.47821.7501-12.7348-1.2802QC'd by RTI0
Inactive04-5.325610.342617.61940.57120.0244-3.26097.5111-2.0198-8.749311.648117.2377-0.455818.491-5.3256QC'd by RTI0
Inactive04-2.2429-0.615848.25450.97410.68273.19743.0502-8.7061-3.674-0.16290.075913.3073-1.0945-2.2429QC'd by RTI0
Inactive04-10.35541.94890.3345-14.3205-1.785337.5999-0.361-5.6006-0.37440.41158.77745.61790.9142-10.3554QC'd by RTI0
Inactive04-1.5991-9.4569-0.1528-3.1449-1.0509-3.54640.99950.947118.9556-1.61920.3341-1.49712.0468-1.5991QC'd by RTI0
Inactive0-4.7754.44950.37865-0.875740 0 0 0 0 0 0 0 0 0 0 0 0 0 05.47123.7148-0.2315-2.9791-1.7564-6.14641.665-3.30124.05251.3643-0.99013.8074.38075.4712QC'd by RTI0
Inactive040.19390.2492-7.583-8.0028.06760.7863-0.734212.71667.5465-8.7219-0.40080.250716.35730.1939QC'd by RTI0
Activator62.154950.921210Single point of activity-4.20654.95490.801951.65950.738330 0 0 0 0 0 0 0 0 0 0 0 0 0 042.82937.78174.8067-6.8947-0.39036.5057-2.03177.1248-10.4951-2.5023-2.07493.7113.790842.8293QC'd by RTI0
Inactive0-7.73824.95490.3412-3.3808740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1951-4.33049.738914.0226-11.5674-5.2995-4.6299-9.9209-0.6342-3.21060.26890.5118-0.5797-0.1951QC'd by RTI0
Inactive0-7.94991.59360.5942-10.86451.540 0 1 0 0 0 0 0 0 0 0 0 0 0 0-13.27140.675922.1412-5.3008-7.8279-10.7766-9.9332-7.8001-13.4679-12.9848-9.7006-10.3588-7.1505-13.2714QC'd by RTI0
Inactive041.08380.07883.7298-2.0071-1.5681-0.18352.2990.5113.6746-1.301160.652-2.0522.57431.0838QC'd by RTI0
Inactive04-3.5534-7.9896-16.56040.5208-13.160.2883-3.32820.5396-5.1164-2.8324-5.6343-5.7751-14.1456-3.5534QC'd by RTI0
Inactive04-13.063930.2518-12.6791-0.5123-9.208519.9477-13.359-9.2717-7.6776-1.8805-11.0769-9.41010.5771-13.0639QC'd by RTI0
Inactive04-4.5943-4.76663.0544-2.0187-6.4339-21.249-8.7037-9.3713-16.543-13.2255-7.6803-1.6375-4.5606-4.5943QC'd by RTI0
Inactive044.6366-6.1501-14.813311.0008-9.6366-12.26414.5909-10.3186-0.1834-8.2404-12.8158-19.41014.14224.6366QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV102
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator48.5771245.234742Partial curve; high efficacy-4.31363.19250.9861244.2224-1.01232.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0197.59092.79990.1145-10.14374.44932.4614-6.04860.71051.36361.1909-17.903610.344856.546197.5909QC'd by Io-li-tec0
Inactive040.921-4.522-0.41033.610311.30590.77741.770816.4277-1.92156.19158.88380.14372.33590.921QC'd by Io-li-tec0
Inactive0410.36171.98465.86320.691513.9728-8.2141.7669-1.733410.36541.9563-16.2694-0.96155.587710.3617QC'd by Io-li-tec0
Inactive0419.11891.42224.2838-10.202618.81053.85119.9584-0.26199.97270.63275.67220.66851.733219.1189QC'd by Io-li-tec0
Inactive044.9626-0.51480.2643-2.48815.4682-2.6876-2.17884.222-2.94051.89871.08380.04550.50564.9626QC'd by Io-li-tec0
Inactive040.666615.237712.80390.573-4.6041-6.116828.7912.07083.966632.36930.0564-4.3988-7.34960.6666QC'd by Io-li-tec0
Inactive0414.473616.574547.836113.5522-0.505110.7274-1.01738.43479.27983.03456.2718-1.6326-0.845314.4736QC'd by Io-li-tec0
Inactive04-10.93880.9715-19.86310.618967.7971-3.03722.85650.89670.377-13.56010.29383.74670.5731-10.9388QC'd by Io-li-tec0
Inactive04-9.69010.69590.797410.37719.1637-0.28360.280360.29770.4062-7.7797-2.510311.50868.7765-9.6901QC'd by Io-li-tec0
Activator34.9795186.5640Partial curve; high efficacy-4.45622.25260.9257192.51965.95972.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0165.39490.27068.518211.26572.124510.91211.902349.02480.52182.29820.913220.0771102.9932165.3949QC'd by Io-li-tec0
Activator49.098218.583142Partial curve; high efficacy-4.30892.84730.9843221.91493.33182.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0175.28820.122813.9777-4.7243.8828-0.35-0.285-4.71078.6067-0.45376.478419.520557.0117175.2882QC'd by Io-li-tec0
Inactive04-0.3737-1.107-9.668117.595-6.9267-10.3374-12.3277-2.1882.4052-1.17882.22392.617411.879-0.3737QC'd by Io-li-tec0
Inactive043.4616-8.92793.13720.14691.52971.278918.8175-8.2727-0.19259.8072-6.48620.9155-0.52463.4616QC'd by Io-li-tec0
Inactive048.563713.5480.34699.3476-2.6914.94942.018919.73492.46752.37712.427117.03134.73388.5637QC'd by Io-li-tec0
Activator27.3808159.306341Partial curve; high efficacy-4.56262.25260.9599163.01573.70942.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0160.765-5.4521-5.93864.82799.441613.8086-0.7263-2.86369.54916.077429.232924.0734109.8075160.765QC'd by Io-li-tec0
Inhibitor21.586448.50270Partial curve; partial efficacy-4.66581.80790.9014-45.57362.9292-2.21 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.655111.34760.2120.84081.3901-0.5055.73414.20017.1735-0.6014-0.3582-16.2507-25.0853-45.6551QC'd by Io-li-tec0
Inactive0-4.65634.95490.78220-2.722840 0 0 0 0 0 0 0 0 0 0 0 0 0 018.4823-8.925-3.1228-4.5617-9.0141-1.0521-3.24460.38692.29351.3176-0.1971-0.80919.541518.4823QC'd by Io-li-tec0
Inactive04-8.192713.8353-7.2564.16614.507710.2991-5.9204-7.47324.34837.52920.4548-0.419-3.3211-8.1927QC'd by Io-li-tec0
Inactive0-4.70824.95490.3819-11.45333.540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.68851.95795.4750.47170.0687-0.588-1.45140.09434.75925.974216.7359-0.8378-10.37770.6885QC'd by Io-li-tec0
Activator43.7266216.690142Partial curve; high efficacy-4.35933.51170.9877217.38730.69722.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0191.6996-0.8544-4.31951.60940.8589-1.6148-2.3097-2.03138.6376-1.175410.52070.084462.886191.6996QC'd by Io-li-tec0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV139
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive043.04154.55111.35572.7957-0.44341.200111.24159.028416.754511.4820.28287.66518.56833.0415QC'd by ACC0
Inactive042.80137.59139.0495-0.62091.0747-4.732-4.46283.86437.69258.74097.95195.34411.21212.8013QC'd by ACC0
Inactive041.15981.7604-0.22671.90895.94328.72113.24918.04034.816-2.75513.51253.0534-0.94291.1598QC'd by ACC0
Inconclusive26.832532.580110Partial curve; partial efficacy; poor fit-4.57134.95490.805134.51.91992.40 0 0 0 0 0 0 0 0 0 0 0 0 0 029.8311-0.8721-1.08398.5472-0.2707-2.98341.93162.21267.42190.46931.66170.87984.811929.8311QC'd by ACC0
Inactive040.2839-2.1772-4.0697-10.3698-5.3113-1.35040.703-1.2597-2.0218-1.4166-10.3579-5.9102-1.08270.2839QC'd by RTI0
Inactive0-4.21954.95490.846226-2.667540 0 0 0 0 0 0 0 0 0 0 0 0 0 020.2771-5.47172.0152-3.5825-3.3714-1.09141.7732-4.0712-2.6175-1.0389-2.4335-3.0234-3.990720.2771QC'd by RTI0
Inactive042.2414-11.1994-4.6871-3.5437-8.6886-2.9094-5.7258-5.7803-0.8894-3.407-0.0539-8.0904-4.17942.2414QC'd by RTI0
Inactive041.9585-2.7596-1.74510.0148-4.8337-1.70010.0338-3.6923-2.34720.0595-3.2137-5.6786-0.76731.9585QC'd by RTI0
Inactive04-1.2619-3.1948-7.7788-2.6046-0.4272-3.8295-3.7003-6.42012.7058-0.646-6.679-1.5059-0.1652-1.2619QC'd by RTI0
Inactive0-6.95130.80.3266-4-15.958640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.8899-9.0312-20.9319-9.595-14.744-10.8356-4.4105-14.11951.5086-6.789-7.2061-4.5666-6.5360.8899QC'd by RTI0
Inactive04-3.3095-0.48-2.8029-2.6833-1.9348-6.4255-1.2732-5.4438-2.2023-0.269-2.0488-2.7756-3.176-3.3095QC'd by RTI0
Inactive04-6.2279-5.8977-5.88853.0356-1.2895-3.4388-1.20891.3533-0.5692-3.48181.1139-4.28792.5505-6.2279QC'd by RTI0
Inconclusive24.744344.72610Partial curve; partial efficacy-4.60654.0950.940841.1917-3.53432.20 0 0 0 0 0 0 0 0 0 0 0 0 0 044.0163-2.326-0.5189-5.79-5.8514-7.0135-7.5286-1.7206-1.05-1.3436-7.19868.106230.24144.0163QC'd by RTI0
Inactive0-6.48820.60.4378-5.05590.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.2571.1563-0.0412-2.31731.01731.301-5.2474-1.2771-1.2256-3.5762-9.2133-1.5659-4.2972-2.257QC'd by RTI0
Inactive041.8503-2.824-6.66650.38150.0316-0.4001-2.9574-1.9037-1.82770.926-2.0444-2.0401-3.64381.8503QC'd by RTI0
Inactive04-8.135-1.0458-14.3819-1.9576-0.5344-0.84050.22110.9001-5.1908-0.19790.34280.5153-3.1524-8.135QC'd by RTI0
Inactive04-4.8676-3.4019-0.2134-1.9475-2.001-1.48782.1253-0.3133-0.7547-0.5741-2.5822-4.01362.2601-4.8676QC'd by RTI0
Inactive0-4.19194.95490.913620.5-1.770440 0 0 0 0 0 0 0 0 0 0 0 0 0 016.518-2.8047-0.6856-0.3257-3.5587-2.7511-3.1164-0.8354-0.54980.5051-2.3554-3.3496-0.3916.518QC'd by RTI0
Inactive041.94490.2436-4.13640.522.1437-2.00670.0618-2.57855.17036.2611-0.45921.30721.80131.9449QC'd by RTI0
Inactive04-5.4278-1.5878-1.3398-6.784-0.1498-7.6982-5.6898-6.1672-4.459-3.0497-0.3927-6.3544-4.354-5.4278QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:hypoxia-inducible factor 1 alpha subunit [Homo sapiens]
External ID: HIF177
Protocol: Please refer to other AIDs 1224846, 1224844, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the HIF-1 agonist mode assay (AID 1224846), cell viability counter screen (AID 1224844), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSupplier
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveVitas
inactiveinactive0inactive0inactive0inactive0inactiveSpecs
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveMicrosource
inactiveinactive0inactive0inactive0inconclusive agonistinactiveSpecs
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveBosche
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveVitas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusive agonistinactiveLightBiologicals
inactiveinactive0inactive0inactive0inactive0inactiveLightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid stimulating hormone receptor [Homo sapiens]
External ID: TSHR992
Protocol: Please refer to AID 1224843 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities results from the TSHR agonist mode assay (AID 1224843). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)615 nm Activity615 nm Potency (uM)615 nm Efficacy (%)665 nm Activity665 nm Potency (uM)665 nm Efficacy (%)Supplier
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:nuclear receptor subfamily 1, group I, member 3 [Homo sapiens]
External ID: CAR220
Protocol: Please refer to other AIDs, 1224839 and 1224836, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the CAR agonist mode assay (AID 1224839) and cell viability counter screen (AID 1224836). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAgonist ActivityAgonist Potency (uM)Agonist Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist0.00491587440.5503939inactive0Selleck
active agonistactive agonist0.03904817536.02134645inactive0Tocris
active agonistactive agonist0.16353462843.96358481active agonist12.5009512284.84392708GVK
active agonistactive agonist0.33081998824.57079327inactive0Pharma
active agonistactive agonist0.50970984344.60374407inactive0SigmaAldrich
active agonistactive agonist0.53080386443.79624313active antagonist25.60161774-36.34968564Vitas
active agonistactive agonist0.55579136842.28539033active antagonist21.29340581-71.57094504Toronto Research
active agonistactive agonist0.61887186947.84406761active antagonist21.95840253-67.8152236Vitas
active agonistactive agonist0.69305867523.44734303inactive0SIGMA
active agonistactive agonist0.74978038667.57701705inactive0Sequoia
active agonistactive agonist0.80955685333.81552342inconclusive antagonist51.47314294-36.72382981SIGMA
active agonistactive agonist0.81518918436.19518688inconclusive antagonist54.48267328-47.49514551Sigma Chemical Company
active agonistactive agonist0.8741797539.64691387inactive0Bosche
active agonistactive agonist0.91962279440.41970881active antagonist3.804314335-58.83188651Vitas
active agonistactive agonist0.96885416145.67191945inactive0SIGMA
active agonistactive agonist0.99652844742.00291176inactive0SIGMA
active agonistactive agonist1.10895524839.48765734active antagonist53.48689088-61.16086801SIGMA
active agonistactive agonist1.12960101953.96975424active antagonist6.352213339-60.65508981SIGMA
active agonistactive agonist1.26743318965.48694129inactive0LightBiologicals
active agonistactive agonist1.28312039740.37685492inactive0Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:nuclear receptor subfamily 1, group I, member 3 [Homo sapiens]
External ID: CAR558
Protocol: Please refer to other AIDs 1224838 and 1224837 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the CAR antagonist mode assay (AID 1224838) and cell viability counter screen (AID 1224837). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAntagonist ActivityAntagonist Potency (uM)Antagonist Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active antagonistactive antagonist0.029849295-112.5989031active antagonist0.161535287-92.43221464Selleck
active antagonistactive antagonist0.039048175-114.2426168active antagonist0.219584025-47.7170068GVK
active antagonistactive antagonist0.201283251-139.5018201active antagonist1.424976291-88.48009673SigmaAldrich
active antagonistactive antagonist0.138548153-128.784838active antagonist3.101706799-63.14155548Bosche
active antagonistactive antagonist0.174421791-123.4441969active antagonist4.057582967-89.67194345Microsource
active antagonistactive antagonist0.026603212-97.41352858active antagonist0.087417975-61.2803848GVK
active antagonistactive antagonist0.449702266-142.1196017active antagonist1.722893406-89.63292438Sigma DiscoveryCPR
active antagonistactive antagonist0.069438566-98.57429404active agonist21.95840253944.4990598Prestwick
active antagonistactive antagonist0.400797566-127.8309906active antagonist1.722893406-86.40756542SIGMA
active antagonistactive antagonist0.246377329-118.072959active antagonist3.90481751-60.4793801Tocris
active antagonistactive antagonist0.31017068-117.4079348active antagonist2.560161774-88.85223199Sequoia
active antagonistactive antagonist0.643083562-131.5734854active antagonist5.731488281-92.60138254Sequoia
active antagonistactive antagonist0.032230527-79.19766633active antagonist0.101921876-39.51345173Tocris
active antagonistactive antagonist0.083098224-89.92277055active antagonist0.485577337-67.3587307Astellas Pharma
active antagonistactive antagonist0.286341893-109.4100987active antagonist0.940917528-59.06750299SIGMA
active antagonistactive antagonist0.04216325-77.88711502inactive0Prestwick
active antagonistactive antagonist0.88451444-131.0330354active antagonist3.261156149-110.0738208Spectrum Chemical
active antagonistactive antagonist0.166814946-96.87831543active antagonist6.269529643-115.9567276LKT Lab
active antagonistactive antagonist0.118832183-90.03043134active antagonist3.101706799-59.80740604SIGMA
active antagonistactive antagonist0.343762429-105.7315439active antagonist66.0072656-37.72360778LightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1A1
External ID: CHEMBL2076234
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Am. J. Physiol.
Year: 1996
Volume: 270
Issue: 1
First Page: F326
Last Page: F331
DOI: 10.1152/ajprenal.1996.270.2.f326

Target ChEMBL ID: CHEMBL1781859
ChEMBL Target Name: Solute carrier organic anion transporter family member 1A1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
9.8Ki=9800nMinhibitor [Ki=9.8uM]
15.7Ki=15700nMinhibitor [Ki=15.7uM]
1.3Ki=1300nMinhibitor [Ki=1.3uM]
5.4Ki=5400nMinhibitor [Ki=5.4uM]
1.3Ki=1300nMinhibitor [Ki=1.3uM]
200Ki>200000nMinhibitor [Ki>200uM]Outside typical range
1.1Ki=1100nMinhibitor [Ki=1.1uM]
2.4Ki=2400nMinhibitor [Ki=2.4uM]
1.6Ki=1600nMinhibitor [Ki=1.6uM]
76.2Ki=76200nMinhibitor [Ki=76.2uM]
9.7Ki=9700nMinhibitor [Ki=9.7uM]
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV292
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.31012.72020.9178130.50640 0 0 0 0 0 0 0 0 0 0 0 0 0 010.20720.11691.0877-0.82831.40810.2240.44220.76721.39391.5438-0.52370.24463.980310.2072QC'd by LightBiologicals0
Inactive04-1.00310.455-0.67910.1097-0.0294-0.3209-0.37240.3015-2.9009-0.9527-0.64320.03660.1488-1.0031QC'd by LightBiologicals0
Inactive04-9.16830.0869-0.6701-0.08740.2948-0.4295-0.4940.2003-0.30420.2523-3.3942-5.4731-5.7204-9.1683QC'd by Acros0
Inactive0-4.31013.51170.9507-25.0034-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.8362-0.4896-1.99840.3098-1.4204-1.1063-1.5973-2.1128-1.7691-0.4168-3.97930.2084-7.1505-20.8362QC'd by SIGMA0
Inactive0-4.71011.41630.9233-16.3759-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.06320.58450.4616-0.06850.1124-0.0471-0.6224-0.7456-3.1099-1.0709-2.8889-7.0663-11.7943-14.0632QC'd by TCI0
Inactive04-0.1154-0.97120.01120.59710.47560.9356-0.6754-0.2241-0.0015-0.2312-0.8380.08420.3198-0.1154QC'd by SIGMA0
Inactive042.90551.4095-0.52852.56062.61722.3687-0.11732.0740.9379-0.23222.14080.43640.55052.9055QC'd by SIGMA0
Inactive040.4365-2.4513-0.0327-0.14261.6133-0.5704-1.3037-0.4536-0.8740.3518-1.20130.9376-1.70620.4365QC'd by Enamine0
Inactive04-0.4372-0.38510.8434-0.56520.5908-0.8441.5676-0.49420.14072.735-0.92472.0890.0301-0.4372QC'd by Astellas Pharma0
Inactive040.2805-0.57020.08670.190.13910.7228-0.40230.5939-0.08271.22771.56540.84720.1071-0.09450.2805QC'd by SIGMA0
Cytotoxic13.8006104.659882Complete curve; high efficacy-4.86011.50950.9746-106.1752-1.5154-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.0220.44760.6282-0.51490.5417-0.18921.52460.7998-10.1237-19.7042-19.2339-57.3648-93.6289-93.022QC'd by LightBiologicals0
Inactive04-0.39550.69810-3.06970.47780.4618-1.9546-1.961-1.23861.8886-1.5214-1.116-4.356-0.3955QC'd by SIGMA0
Inactive041.64271.72030.0899-0.02840.55570.76330.37690.7462-0.11642.84762.2382.29760.06821.6427QC'd by SIGMA0
Cytotoxic54.947737.36420Single point of activity-4.26013.67720.955-38.364-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.3034-0.2157-0.2184-0.94891.6034-0.1225-0.1335-1.1928-0.5138-0.4285-1.2985-6.4623-5.9048-30.3034QC'd by SIGMA0
Inactive04-2.6646-0.61930.7292-0.0404-0.8078-0.162-0.5396-1.2322-3.6502-2.93792.9929-2.3902-4.2836-2.6646QC'd by SIGMA0
Inactive04-0.1215-0.22550.433-0.2813-0.5615-0.3215-0.6703-1.9336-2.5044-0.0953-0.5624-1.2739-0.3684-0.1215QC'd by FLUKA0
Inactive04-0.4775-1.05130.15671.3131-0.7122-1.1962-0.9485-0.0481-2.22321.37960.04690.6934-2.729-0.4775QC'd by SIGMA0
Inactive042.5338-0.1122-0.54020.52120.06360.0597-0.09260.1726-0.30530.89490.6631-0.32610.8712.5338QC'd by SIGMA0
Inactive0-4.31013.990.9457-19.4313-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.6094-0.0324-2.4557-2.2868-0.0647-0.7762-0.724-0.8002-1.03751.38830.8393-0.3638-3.9235-16.6094QC'd by SIGMA0
Inactive04-2.3612-0.93230.606-0.64620.11111.8175-0.12220.08420.31443.2040.06781.7962-1.3361-2.3612QC'd by SIGMA0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:15218 靶标:N/A
External ID: ES_Opera
Protocol: To perform high content microscopy screening, HeLa cells with stable expression of F508del-CFTR were cultured in 96-well PE ViewPlates (Perkin Elmer, Waltham, MA) for one day prior to well by well addition of two thousand known bioactive compounds from the NIH Roadmap Molecular Libraries Small Molecule Repository. Ten mM DMSO stocks of compounds were diluted 500-fold in growth medium, then added in equal volume to assay plates to yield a final screening concentration of 10 M.
After a 24h treatment period, cells were fixed, permeabilized, and labeled with 3G11 antibody, which recognizes intracellular CFTR epitopes in NBD1, then visualized with AlexaFluor488 anti-mouse conjugate and DRAQ5 fluorescent DNA label (Axxora, Farmingdale, NY). Nine microscopic fields per sample well were then imaged using the Evotec Operatrade mark QEHS automated confocal microscope equipped with a 20x magnification Olympus objective lens (Perkin Elmer). Automated analysis of the resulting images was performed using Acapellatrade mark (Perkin Elmer) software as follows. High contrast labeling of cellular nuclei by DRAQ5 enabled rapid image segmentation by intensity threshold. Corresponding cytoplasm and cell margins associated with each nucleus were subsequently defined by image threshold of lower contrast cytoplasmic / RNA staining of DRAQ5. Further segmentation of images into regions of interest for analysis included plasma membrane (a 2 pixel wide region corresponding to cell margin) and perinuclear region (a 5 pixel wide region encircling the outside of the nuclear mask). Three criteria were used to track expression and subcellular localization of: 1) F508del-CFTR signal in the region of interest, designated as the plasma membrane (PM); 2) F508del-CFTR signal in the perinuclear region of the cell, as a proxy for the ER; and 3) fluorescence signal across the entire cell (Total) to monitor total F508del-CFTR protein. Each measurement was expressed as the mean fluorescent intensity for all cells imaged in 9 microscopic fields per sample.
Comment:
PM_IntensityTotal_IntensityTested_Concentration
808610
788810
11013410
727810
909210
9610210
909610
9910610
717710
869010
949410
838810
929610
929210
858510
9911410
909410
728010
889110
939710
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:HNF4 Alpha
External ID: BHood-p-21Jun2013-01
Protocol: This assay is to identify inhibitors of HNF4 alpha protein binding to DNA
##

A. Materials:##
Description#Company#Cat #
1M TRIS #BioRad#161-0719
DTT#RPI#D11000
Glycerol#Amersco #0854-1L
NaCL#Fisher Bioreagents#BP358-212
Tween 20#Sigma#P1379
HNF4 Protein #Assay Provider#
FITC-DNA#Assay Provider#
1536 well black high base plate#Aurora#00019120BX
##
B. Plate Map:##
Positive control in columns 1 and 2 is DNA and 70nM Protein##
Negative control in columns 3 and 4, Protein at 650nM and DNA, DMSO##
Test compound in columns 5 - 48, Protein at 70nM + DNA + test compound

C. Procedures:##########
Step#Description#########
1#Transfer test compounds to columns 5-48, DMSO to columns 1-4 using ECHO 555.#########
2#Set up Envision as as described in G. Instrument setting.#########
3#Prepare assay buffer.#########
4#Dispense undiluted HNF4 protein solution at into col 3-4 and 140nM HNF4 protein into columns 1,2, and 5-48. #########
5#Dispense 3uL/well of FITC-DNA (FAC = 5nM) using BioRAPTR#########
6#Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute.#########
7#Incubate plates at RT for 1 hour.#########
8#Read using FP protocol on Envision#########
##########
D. Assay Conditions:##########
Reagent##Final Conc.#Unit#######
1#Tris pH7.4#0.02#M#######
2#NaCl#0.05#M#######
3#DTT#0.01#M#######
4#Glycerol#10#%#######
5#Protein#650 for EC100 and 70nM for EC20#uM#######
6#DNA#5#nM#######
*#6uL reaction volume#########
*#60 min reaction at room temp#########
*#10uM test compound#########
*#0.5% DMSO
Comment:
%Activity_Corrected at 10 uMValue at 10 uMMean HighSTD Deviation HighMean LowSTD Deviation Low
-6.39105.0999985116.057.38199.696.53
-0.54109.8000031116.057.38199.696.53
-0.14111.9000015116.057.38199.696.53
3.17114.4000015116.057.38199.696.53
0.67110.0999985116.057.38199.696.53
-1.92108.3000031116.057.38199.696.53
-1.35108.0999985116.057.38199.696.53
1.56110.5999985116.057.38199.696.53
1.88112.1999969116.057.38199.696.53
1.69111.5999985116.057.38199.696.53
-0.73109.9000015116.057.38199.696.53
-0.36111.1999969116.057.38199.696.53
9.41119.5999985116.057.38199.696.53
-0.85109.3000031116.057.38199.696.53
-0.03110.0999985116.057.38199.696.53
2.36112116.057.38199.696.53
3.01113.1999969116.057.38199.696.53
-0.42109.0999985116.057.38199.696.53
-1.98107.5999985116.057.38199.696.53
0.83108.9000015116.057.38199.696.53
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV261
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.26620.67031.4763-7.86010.62961.6439-0.485110.60941.2638-0.77391.2431-0.534713.4202-0.2662QC'd by SigmaAldrich0
Cytotoxic31.2778102.254240Partial curve; high efficacy-4.50482.25260.968-103.8742-1.62-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-90.6406-2.95951.25795.559-9.0576-2.3901-8.7951-2.9108-3.27020.8382-3.4053-9.3391-64.5158-90.6406QC'd by Sensient0
Cytotoxic10.931394.762982Complete curve; high efficacy-4.96133.06540.9629-95.2905-0.5276-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.7395-1.27940.67685.0387-3.7769-0.1919-0.1178-1.6869-4.2628-2.6139-3.114-87.8216-90.2372-87.7395QC'd by Io-li-tec0
Inactive0004-2.41291.3956-4.16373.5243-5.8685-1.01070.51760.1618-4.9932-1.0057-1.2821-7.4184-5.5068-2.4129QC'd by SIGMA0
Cytotoxic35.40992.769440Partial curve; high efficacy-4.45092.33320.9808-91.15061.6187-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-77.38681.09870.239611.4258-0.50932.3570.5258-1.95311.68720.28711.9844-9.716-46.1242-77.3868QC'd by Io-li-tec0
Inactive0-7.50970.30.5207-3.81855.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9173.66120.12352.2133-0.8421.10190.9559-1.6737-0.1244-3.1217-2.039-6.93210.8766-2.917QC'd by SIGMA0
Inactive00042.27361.34564.39256.24761.83614.5650.6623.17661.92281.67570.95962.41711.75032.2736QC'd by SIGMA0
Inactive0-6.96134.95490.4857-2.0409340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11740.89896.65672.81771.334.05530.0163-5.219-1.87890.2926-0.0570.4195-2.2-7.1174QC'd by SIGMA0
Inactive0-4.70014.95490.5914-15.9637-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9613-4.1830.41095.569-1.66683.59060.2077-3.2723-1.38830.16930.2608-3.8346-14.9697-2.9613QC'd by SIGMA0
Inactive0004-2.3622-1.9219-0.34070.2774-0.4936-0.478-0.2306-1.8006-2.55650.0517-2.204-2.8226-6.1715-2.3622QC'd by SIGMA0
Inactive0-4.26964.95490.8419-27.0571-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.9643-1.66630.02590.308-4.1056-8.1214-0.0418-5.5982-0.4306-0.8456-1.5064-1.6208-3.9632-22.9643QC'd by SIGMA0
Inactive0004-1.6236-0.746-2.39663.4819-4.7806-0.1932-1.6365-5.8763-1.47840.01-6.9774-0.07040.0356-1.6236QC'd by SIGMA0
Inactive00040.7707-3.27651.3611.555-0.1221-0.3791.1184-2.0405-0.63510.218-4.9126-6.1749-0.3660.7707QC'd by SIGMA0
Inactive00042.5308-1.9447-2.24992.66670.06382.30611.48490.1054-2.817-0.6612-2.8286-5.24455.13872.5308QC'd by SigmaAldrich0
Inactive00040.3151-0.1759-6.8242.3532-2.5273-0.0411.77952.35540.1109-7.2061-2.8467-6.05672.3370.3151QC'd by SIGMA0
Inactive0-4.66184.95490.471210-2.596140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.1799-3.424-2.9862-0.6424-3.6038-3.1177-1.9168.0763-3.7778-5.8514-4.0513-3.577310.8157-1.1799QC'd by SIGMA0
Inactive0004-5.9223-6.2685-3.7694-1.61-7.6686-4.6601-1.27066.9517-1.775-3.8643-5.3257-4.44672.4221-5.9223QC'd by SigmaAldrich0
Inactive0004-4.029-2.29010.632725.6927-3.2026-3.0528-1.48314.15260.8397-2.6293-3.2865-1.796615.5972-4.029QC'd by Io-li-tec0
Inactive0-7.64790.30.57453-8.730640 0 0 0 0 0 0 0 0 0 0 0 0 0 01.52-5.5283-5.9036-1.2224-4.2271-1.55110.8611.371-2.04390.27432.471-0.70294.9081.52QC'd by SIGMA0
Inactive0004-0.24473.46312.74895.92733.97262.71541.23241.88212.87492.86910.75010.8324-1.1026-0.2447QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV775
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-0.96590.8898-4.8159-4.8051-10.85392.00630.2658-3.4476-3.5183-4.60534.276-0.2087-4.0597-0.9659QC'd by ChemService0
Activator22.68377.500310Single point of activity-4.64434.95490.899578.921.419730 0 0 0 0 0 0 0 0 0 0 0 0 0 128.23131.0977-2.20470.21540.57129.35350.12394.7513-4.071613.57114.13074.155782.527728.2313QC'd by Alfa Aesar0
Inactive0-8.79692.40640.70060.50351840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.84039.82273.6174-2.9137-1.116-0.04373.65163.39430.6174-1.2787-0.46133.71932.1743-2.8403QC'd by SIGMA0
Inactive0-7.96354.95490.3891-3.02169.540 0 0 0 0 0 0 0 0 0 0 0 0 0 112.70322.890922.51063.3877-7.68681.3786-3.89096.7609-5.6448-8.5965-8.816-2.24533.572912.7032QC'd by SIGMA0
Inactive04-7.5796-6.7661.04820.597159.63963.81297.15211.4315.94461.46332.5613-0.2268-9.7763-7.5796QC'd by SigmaAldrich0
Inactive04-0.55682.99589.14274.796.269-1.11660.9079-0.585215.42052.85479.924113.83452.6138-0.5568QC'd by SigmaAldrich0
Inactive0-4.96744.95490.34836.5-4.520140 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5242-3.6931-0.2524-8.4996-11.50323.1295-2.48742.0546-5.6624-8.1819-12.51138.43910.713210.5242QC'd by ChemService0
Inactive0420.790748.63253.30592.09523.51677.0478-0.132413.46681.409410.74818.92113.8-0.12720.7907QC'd by SIGMA0
Inactive0-4.8524.95490.5238-10.35554.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.57912.2632-2.22510.158212.07365.32462.9693.94422.435319.18123.8473-3.6889-13.2129-7.5791QC'd by SIGMA0
Inactive040.85620.9645-3.5889-6.6697-0.2872-18.1507-0.3668-0.2892-14.71464.854513.73898.332-6.90480.8562QC'd by SIGMA0
Inactive0-5.87274.95490.37767.5-4.091640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.1552-3.9611-10.38332.6661-8.960.1820.26360.4745-5.795621.96346.0559-2.48545.2743-7.1552QC'd by SIGMA0
Inactive0-4.56444.95490.506-15.76975.540 0 0 0 1 0 0 0 0 0 0 0 0 0 0-14.8081-4.570811.00963.369864.7731-2.1070.999212.957810.16817.088213.26596.132-11.628-14.8081QC'd by SigmaAldrich0
Inactive04-3.2157-5.7722-7.396213.7068-0.731-5.3098-0.270911.3982-1.62083.9786-12.3964-9.555-1.1499-3.2157QC'd by SIGMA0
Inactive0-7.25934.95490.32-6.12140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.7215-4.4043-1.546713.9538-0.1176-2.2902-7.2216-8.1463-3.6229-4.6362-10.1-8.0031-6.611-2.7215QC'd by SIGMA0
Inactive04-4.39-6.4733-0.408524.1053-4.3893-9.8384-3.13613.477-3.2614-7.9234-10.35339.4605-3.1213-4.39QC'd by SIGMA0
Inactive040.7154-2.805716.6851-6.8951-1.42365.78640.5672-2.57540.357-0.8413-0.0373-0.2343-2.41890.7154QC'd by SIGMA0
Inactive0-7.91083.1320.32694-6.391140 0 0 0 0 0 0 0 0 0 0 0 0 0 05.1373-3.1578-13.24260.37320.71293.87065.6246.08533.058-0.3775-0.69230.424616.27635.1373QC'd by City Chemical0
Inactive0-4.36143.51170.6129-30.525.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-25.87477.310911.1854.75950.721.86111.188923.82980.9363-5.034812.54485.3932-6.344-25.8747QC'd by Sensient0
Inactive0418.96081.66133.767-0.99175.7941-1.7954-0.53653.42689.26066.3378-0.4530.53757.376218.9608QC'd by SIGMA0
Inactive043.573315.28766.21377.7355-1.7164.0531-4.721445.2796-6.5581-9.994412.3176-6.02470.1453.5733QC'd by SIGMA0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV408
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive048.53831.49545.51920.79227.009-0.8478-0.03192.28538.8413-4.3787-3.13581.45057.65388.5383QC'd by ACC0
Inactive040.49651.0548-0.31072.1965.22131.8741-1.0574-11.3835-0.034615.49621.23434.7392-0.03050.4965QC'd by ACC0
Cytotoxic16.930137.055920Partial curve; partial efficacy; poor fit-4.77132.72020.7119-30.05317.0028-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.2896-4.00955.44459.1825.66294.06920.63465.94055.89723.76626.44865.7617-12.7125-26.2896QC'd by ACC0
Inactive042.29623.0087-1.99717.18371.73190.52393.82442.269810.106-1.31745.0870.692715.7782.2962QC'd by ACC0
Inactive04-14.63-1.5501-9.9374-3.0134-4.4328-2.88331.1197-5.299813.52320-2.76717.1454-1.0799-14.63QC'd by RTI0
Inactive04-6.02471.2321-0.0859-5.3557-13.39742.28822.2565-8.7707-0.1147-6.1694-8.39860.084-6.288-6.0247QC'd by RTI0
Inactive04-3.7135-3.2997-3.7414-5.8868-12.6672-0.8641-1.4917-1.2248-1.4817-2.8215-6.8492-0.4051-4.8669-3.7135QC'd by RTI0
Inactive04-8.9464-8.8617-2.3423-3.563-4.9878-0.3168-0.9864-0.91598.5284-3.3714-12.73545.6937-14.4798-8.9464QC'd by RTI0
Inactive04-8.4909-8.35940.032-7.8769-10.3346-5.7828-3.1047-5.4735.5521-2.1139-3.8009-4.4179-12.9761-8.4909QC'd by RTI0
Cytotoxic56.06946.408121Partial curve; partial efficacy-4.25131.96730.7233-49.073-2.6649-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.5901-1.6294-3.9715-5.215-5.8802-3.0995-0.1987-9.346-0.8796.1445-9.4957-7.4789-15.6045-36.5901QC'd by RTI0
Cytotoxic53.085353.600821Partial curve; partial efficacy-4.2752.40640.7206-53.47040.1304-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-43.4173-1.1372-5.349-1.8973-0.4342-4.2881-0.76361.7769-4.206125.2788-4.97-1.434-22.046-43.4173QC'd by RTI0
Cytotoxic2.292672.807784Complete curve; high efficacy-5.63972.25260.9747-75.9817-3.174-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.1161-3.65840.3853-1.3871-0.3670.3574-4.8789-7.5102-15.117-57.7466-70.3156-62.3401-81.3546-81.1161QC'd by RTI0
Cytotoxic55.3956102.03141Partial curve; high efficacy-4.25651.86170.9254-104.6061-2.5751-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.2471-0.5886-6.1071-1.737-7.6263-2.1359-1.2977-2.4911-1.08084.9562-9.0768-20.2884-31.0764-79.2471QC'd by RTI0
Inactive04-11.9507-4.1317-10.3768-0.0871-1.5726-9.60140.0652-4.8723-1.2808-4.8418-12.8806-5.353-16.723-11.9507QC'd by RTI0
Cytotoxic31.633361.190340Partial curve; high efficacy-4.49991.96730.8483-62.9529-1.7627-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.7891-1.2215-1.8895-3.6905-1.78120.7209-2.316-8.3802-1.19224.8583-15.6308-13.4062-36.5957-62.7891QC'd by RTI0
Cytotoxic24.71783.579740Partial curve; high efficacy-4.6071.210.9158-86.3028-2.7231-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-71.919-1.6524-0.2823-0.7682-13.767-4.1612-2.1857-1.60340.1285-8.3122-29.8628-20.29-59.8611-71.919QC'd by RTI0
Cytotoxic39.910848.969820Partial curve; partial efficacy-4.39893.1320.7479-46.6912.2787-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.8915-1.4724-1.71352.4136-2.42740.6336-1.32852.9565-3.098910.9402-0.76438.9975-21.9495-42.8915QC'd by RTI0
Inactive0-4.19191.3310.6301-38.9316-5.899440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1097-2.9424-8.939-1.5828-14.107-1.7509-3.9946-12.5941-2.2873-4.1107-8.573-9.327-13.3946-29.1097QC'd by RTI0
Inactive0-5.34142.40640.6908-18.919-340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.2635-2.2657-6.0647-2.6148-8.7621-1.4868-5.6785-0.6261-3.5564-1.2527-17.2384-15.5057-20.3492-18.2635QC'd by RTI0
Cytotoxic30.876338.512720Partial curve; partial efficacy-4.51041.3310.8258-41.1094-2.5967-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.0642-4.06730.1117-1.7013-2.9403-0.6733-4.992-1.4145-5.0534-2.0416-19.1431-6.8148-21.1762-38.0642QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV344
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.67134.95490.6549101.284940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.146800.02513.4553-2.26260.26950.44014.0318-0.2863.12986.637112.25044.6241-0.1468QC'd by ACC0
Inactive04-2.605600.38062.6444-0.8901-12.6394-1.3087-3.0560.3820.55453.4646-0.01940.3046-2.6056QC'd by ACC0
Activator18.9959300.141843Partial curve; high efficacy-4.72131.34430.9737302.97472.83292.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0233.776804.7574-0.75475.09110.96012.96235.13960.23320.796128.169383.5125111.6322233.7768QC'd by ACC0
Inactive043.748203.79591.4793.6038-3.2820.11971.4384-0.41570.297810.8637-0.76562.38743.7482QC'd by ACC0
Inactive04-4.96040-4.9633-1.4044-6.0069-2.4696-0.2144-5.30882.3858-9.7548-0.02541.7914-4.0632-4.9604QC'd by RTI0
Inactive04-1.54146.9276-3.29011.7218-1.45891.4621.2447-0.18510.41510.85143.1833-0.1838-4.7946-1.5414QC'd by RTI0
Inactive045.371900.802-4.4806-7.7141-8.7492.6447-4.0542-8.1541-4.99260.73110.1613-4.95695.3719QC'd by RTI0
Inactive04-0.19640-1.1762-1.43460.794-0.2279-1.25663.72962.4954-1.6049-2.622730.7271-3.9862-0.1964QC'd by RTI0
Inactive040.2002-1.6382-1.639512.97330.2813-0.6075-3.66799.9906-3.9057-5.007611.250917.5257-3.76090.2002QC'd by RTI0
Inactive04-10.7760-1.374-16.3867-9.6856-8.8335-8.12680.3586-11.6288-17.550.2134-14.9266-0.4043-10.776QC'd by RTI0
Inactive043.52360-8.06310.119-3.62550.551.2328-4.3353-4.8215-9.46151.31690.7882-4.48953.5236QC'd by RTI0
Inactive04-5.2402-1.631-3.7223-4.049820.9396-4.15646.27670.17740.51692.94763.51113.9943-4.4898-5.2402QC'd by RTI0
Inactive040.13350-0.5332-1.0415-2.76140.94731.12528.07280.1983.19610.038410.1274-1.26910.1335QC'd by RTI0
Inactive042.485905.4776-3.2287-2.492411.30651.29642.79110.3823-0.682512.9564-3.23979.43392.4859QC'd by RTI0
Inactive04-1.052900.14737.26823.4216-0.63920.5348-0.2158-0.82884.36890.46485.01514.0525-1.0529QC'd by RTI0
Inactive048.21080-7.41464.402-3.1366-6.0671-1.21010.24475.5959-5.8949-0.53856.2219-3.00048.2108QC'd by RTI0
Inactive04-12.68710-2.66038.1036-7.2889-2.27283.1657-4.8527-7.9749-5.6664-4.77134.9243-15.3033-12.6871QC'd by RTI0
Inactive047.19110-0.0979-2.0844-0.50311.08660.34060.0709-2.1912-0.489112.82370.7893-4.00177.1911QC'd by RTI0
Inactive04-6.318500.8187-0.30319.563-2.5783-1.9705-5.1937-6.3994-1.1616-0.399913.6198-1.1282-6.3185QC'd by RTI0
Inactive0-4.71044.95490.3797.5-0.152240 0 0 0 0 0 0 0 0 0 0 0 0 0 06.03202.3589-0.0405-2.23747.1608-4.6574.1838-3.6711-3.59410.20892.01118.88176.032QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV608
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-7.91014.95490.36573-4.566540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.497-5.0447-3.1586-2.492211.97450.72283.8462-0.90310.08594.51117.45240.57260.4752-0.497QC'd by LightBiologicals0
Inactive04-4.40016.1277.37653.9732-17.7212-2.1112.9369-2.0138-1.9612-1.764212.23195.3628-2.13280.098QC'd by Acros0
Inactive0-8.21014.95490.33563-1.749140 0 0 0 0 0 0 0 0 0 0 0 0 0 05.5634-1.3307-1.40184.77328.77114.95594.6943-0.7381.5956-0.0592.190.34873.49635.5634QC'd by SIGMA0
Inactive043.70551.17292.93790-0.2228-9.54881.8978-8.10749.541118.06111.6453.6969-1.03733.7055QC'd by LightBiologicals0
Cytotoxic4.896688.376283Complete curve; high efficacy-5.31014.95490.9452-85.76822.608-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.830512.8268-2.6197-8.3186-5.4755-9.2803-1.9474-5.55969.722513.1194-75.9591-88.787-83.6145-81.8305QC'd by LightBiologicals0
Inactive042.15842.0535-7.6545-2.11364.08342.3865-8.52680.2892.7267-18.22342.29387.61751.43972.1584QC'd by SIGMA0
Inactive04-5.3937-4.1455-3.6603-2.2052-4.3322-6.56930.65963.8239-4.3499-2.6615-10.2378-9.0990.1562-5.3937QC'd by TCI0
Cytotoxic54.947737.847820Single point of activity-4.26013.92950.8286-41.3478-3.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2065-2.8063-1.0619-1.1535-11.1607-6.2004-0.9737-6.3091-4.9069-5.5424-0.04442.153-9.6829-33.2065QC'd by SIGMA0
Cytotoxic24.541244.873220Partial curve; partial efficacy; poor fit-4.61010.50.6308-39.87325-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.2718-0.56162.411714.059315.66811.1581.1836-0.6512-6.5098-16.0797-3.6424-3.6892-20.0211-31.2718QC'd by LightBiologicals0
Cytotoxic34.669736.874120Partial curve; partial efficacy-4.46012.40640.6776-36.19650.6776-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.72842.6457-1.8233-1.25981.7444.9434-5.9651-5.9564-3.446717.4959-3.98991.7512-20.3635-30.7284QC'd by SIGMA0
Inactive0-4.81014.95490.4769-11.6033140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.84660.72163.79-3.66135.31625.6131-11.26978.4546-1.82790.64852.3612-4.8275-12.5861-10.8466QC'd by TCI0
Inactive04-15.3343-6.1477-2.54385.61752.0543-8.60916.70164.2089-9.88019.3124-0.79122.42880.8877-15.3343QC'd by SIGMA0
Inactive0-4.57134.95490.3813-15.743-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.95255.2776-9.68751.75232.8732-8.9944-2.1822.7189-0.312-0.3041-2.72720.1017-0.3966-13.9525QC'd by SIGMA0
Inactive0-4.46012.33320.4405-16.6993-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3328-5.4711-1.2162.40880.06260.6089-10.5794-1.90030.58163.5724-1.7139-0.299-10.3989-14.3328QC'd by SIGMA0
Inactive041.3535-3.8080.7096-11.63583.602-1.64566.4772-2.12450.203-1.5066-0.24212.6085-12.46621.3535QC'd by SIGMA0
Inactive0-5.61011.88510.3104-10.1584-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.0046-1.67529.2353-10.96540.3332-1.3167.45820.1397-3.1021-9.4311-9.9917-7.9985-9.7243-2.0046QC'd by SIGMA0
Inactive043.5237-0.2824-0.7839-2.5676-13.10910.26537.76231.1115-7.6587-1.128810.7227-9.6473-12.14623.5237QC'd by SIGMA0
Inactive04-15.2694-0.43230.0711-7.7901-19.56841.5675.88014.11291.37130.8506-0.3304-9.2389-7.9287-15.2694QC'd by SIGMA0
Inactive040.5651-0.08312.2526-8.22182.5641-0.7189-11.0158-10.5852-0.5531-0.0079-0.51660.7582-0.29270.5651QC'd by SIGMA0
Inactive040.2096-3.79912.39421.9929-4.0354-4.7863-3.0068-1.183-0.60184.805-3.8894-4.77883.39830.2096QC'd by Crescent0